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Abst ract
Hctcroclit ic pcptidcs arc peptide seq uence variants with enhanced
inununo gcnicit y relative to reference or wild type pcptidc s. In therapeutic cancer
vaccine s. hctcrocl itic pcptidc s dramatica lly augme nt ce ll-mediated immunity aga inst
tumour antigens by act ivating cytotoxic 'I' lymphocytes (CTL ) against tumour-associated
sclf-pcptidcs. l lctcrocl itic peptidcs could likewise contribute to human
immunodeficiency virus (l lIV) immunotherapy by broaden ing CTL reactivity and/or by
selectively stimulating interlcuk in ( IL)-2- product ion (correlat ed with disease contro l and
non progression) . To invest igate this possibility. we screened peripher al blood
monon uclear ce lls (PBMC) from l ll v -infcc tcd subjects for intcrfero n-y ( lI:N-y) and IL-2
productio n by enzyme- linked inununo sorbcn t spot (ELIS POT) assay with peptide pools
spanning the major 11IV antigens. Pools stimulating IL-2 product ion were dcconvolutcd
with peptide matr ices 10 identify the individua l l Smcrs responsible. Ncf X 3 ~9 1 (1\ 2-7 ).
cf 1 3 5~ 143 (1\2 - X). Gag IX~ 27 (1\3 -2) and Gag 77~ X5 (1\2-Gag) were confirmed as
optimally defined 9me r pcptide s stimulating IL-2 product ion by PBI'vI C from two or more
l ll v-infcctcd individ uals in our cohort. Twen ty-fo ur potent ially hctcrocl itic variant s were
generated with conservative and semi-conservative amino acid substitutions at position s
3. 5 and 7 of these 9mers. An additional 24 variants were genera ted in a simi lar fashion
with Gag 1 47~ 155 (1l57- 1). Gag433 (1\2 -9). and non- IIIV pcptid cs, 1\2-F lu
(G ILGFVFTL) and irrelevant peptid e. 1\2-11' (LLDVPTI\I\ V), I:ighty-six l ll v -inlcctcd
and six l llv- uninlcctcd subjects were then tested for CDX' 'I' cell reactivity again st one
or more o f the variant sets by ELiSPOT assay. at one or more time points. l lctcrocl itic
pcptides enhanced 11.-2 production by CDS+ T cells in 50%. o r cases in which an 11.-2
response was detected and enhanced IFN-y production in 25%.o r cases in which an IF -y
response was detected . Variants that increased IF -y and/or 11.-2 production in
comparison to index pcptidcs werc further tested forhetcroclitic propert ies in cell culture.
Proliferation. differentiation and breadth or reactivity were assessed by
curboxyf l uo rcscc in succinimidyl ester (CFSI:) diluti on. surface and intracellular llow
cytomctry and cytotoxicity assays. I lctcroclitic pcptides stimulated broader reactivity o r
peptide-stimulated CDS' T cells. reduced the exhausted phenotype or responding CDS' T
cells. and. in some cases. enhanced prol i feration or respondin g T cells, I lctcrocl iric
propert ies or particular pcptidcs varied between individual s and. in most eases. within
individuals at different time points. Although we do not know the mechanisms by which
these peptide act. it appears that these pcptides stimulate the same subsets or CDS' T
cells as re ference pcpt idcs but somehow exert differential signaling eff ects. Further
insight into these mechanisms would provide information on hcteroclitic peptide design
for IIIV CDS' T cell cpitopcs and contribute to a basic understanding or the relationship
between T cell receptor: pept ide interactions and T cell funct ion .
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Chapter I Introduction
1.1 IIIV-I summary
Thc World lle alth Orga niza tion (WIIO) estimates that 33 million peop le
worldw ide arc infected with IIIV III . Infect ion with IIIV leads to a gradual loss 01'
immune competence allowi ng op portunistic infect ions that arc not norm ally pathogenic
to become life threaten ing and allow ing certai n cancers to occur. Most untreated
indiv iduals infected with IIIV progre ss over time to acquired immunodeficiency
syndrome (A IDS) 121. Tra nsm ission 01' IIIV occ urs through transfer 0 1' infected bod ily
lluids. namely blood. semen. vagi nal fluid and breast milk. within which IIIV ca n be
present as free virus or con tained within an infected immun e cel l. This transfercan occ ur
through unsafe sex, con taminated needles, co ntaminated breast milk. perinatal
transmission or through infected blood products. although the latter is not as commo n
now due 10 improvements in IIIV screen ing, Two types 0 1' IIIV. IIIV-I and IIIV-2. have
been identified . IIIV-I is more prominent worldwide and leads to a more virulent
infect ion while IIIV-2 is confined to West Africa and is not assoc iated with
immun osuppression 131. This thesis will locus IIIV-1.
1.1.1 Str ucture
Il lY is encoded for by 9 genes (Figure 1.1.1) 141. Envelopc «('111") . group-specific
antigen (gag) and polymerase (po!) genes arc common to all retroviruses and arc required
to make the structural and enzymatic proteins. respectively. for the format ion of new
virus particles. Approximately fourteen "s pikes" 151. trimcrs of the ('/II'-cncodcd
glycoprotcins (gp) gp l20 and gp-ll , arc embedded within the viral enve lope (Figure
1.1.2). gp l2 0 is important for docking of virus particles onto host cells 161. while gp4 1 is
required tor viral fusion and intcrnalization 17. XI. Beneath the outer enve lope lies the
matrix. which maintains the integrity o lthc virus particle and separates the viral envelope
from the capsid. The vira l capsid is made up of - 2.000 copies of gag-cncodcd p24 and
contains two single strands of ll lV ribonucleic acid (RNA) that arc tightly bound lo the
nucleocapsi d protein, p7. and the po!-cncodcd enzymes. reverse trunscriptasc (RT) and
intcgrasc. Each strand of RNA has a com plete copy of the virus' genes - ('/II".gag. and
!IO!. and the remaining 6 regulatory genes. transactivator (tat) , regulator of viral
expression (r(,I") . ncgutivc-rcgulation factor (1/(:/) . viral infectivity (vi f ). viral protein R
tvpr) and viral protein U (l'plI) (Figure 1.1.1). The regulatory genes encode proteins that
control infectivity, replication and pathogenesis of Ill Y. 'lh e long term inal repeat (LT R)
at either end of each strand of RNA is involved in control of Ill Y replication. The po]:
encoded enzymes. reverse transcriptasc. protease and intcgrasc arc responsible for
copying the viral RNA gcnomc into deoxyribo-nucleic acid (DNA). processing immature
gag and gag/pol proteins and integrating the DNA copy oft he lil Y gcnomc into the host
DNA. rcspcctively.
I \
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infect ivity andi s associat ed with d ise ase progressio n
Fi~lIrc 1.1.1 \lIV Gcnc Structure. III V ' s RNA ge nome e nco de s 9 ge nes. whic h arc
flanked by LTR s. Each strand o r RNA has a co m plete co py or the vir us ' ge nes - the :1
s tructura l ge nes CI/I ' . gag. a nd po] . and the rem aining () regul ato ry ge nes . tat, 1'('\ ' . nc] . vi] ,
\ '111' a nd \ 'I JII . T he regul ator y genes e nco de prot ein s that co ntro l in fec tivit y, rep lica tio n and
pa tho gen esis or liI V . T he LT Rs at e ithe r e nd o r eac h strand or RNA a rc in vol ved in
contro l o f I ll V repli ca tion . Ada pted rrom l9. 10 1.
Fi~u re 1.1.2 T he structure (If Ill Y. The viral enve lope is composed or a phospholipid
bilayer. taken from the membrane or a human cel l when a newly formed virus particle
buds. Embedded throughout the viral envelo pe arc trimcrs or {'III'-elH:mk d gp120 and
gp-ll . which mediate viral auac hmcnt and fusion to host cells. The matrix lays beneath
the viral envelope. II maintains the integrity or the virus partic le and separates the viral
envelope from the capsid. The viral capsid is made up or - 2.000 copies or gag -encoded
p24 and contains l W O single strands or Ill Y RNA that arc tightly bound to the
nucleocapsid proteins and the flo/-eneodcd enzymes. RT and intcgrasc, Each strand or
RNA has a complete copy oft he virus' genes. Adapted from 1111.
1.1.2 Tropism
IIIV tropism is dependent on the host cell receptors requ ired fix viral attachment.
The CD4 receptor. expressed on CD41 T cells. macrop hagcs (m<jl) . and dendritic cells
(DC). acts as the primary receptor 1'01' gp120-mediated binding or II IV to target cells 112.
131. In 1996. it was discovered that IIIV relics on the usc o r co- receptors. CC R5 and
CXCR4. to help mediate virus fusion and penetration into the target cell 114-161. The
importance or CC R5 as the predominant co-receptor in IIIV- I infect ion 114. 151 was
highlighted upon the observance that polyrnorphisms in CCR5. particularly a
homozygous 32 base pair (bp) deletion in the coding region (CCR 5-L\32). reduced the
risk o f l llV infection regardless or the mode ortransmission I17-191. lIowever. a few
IIIV' CC R5-L\ 32 individuals with a slower course o r disease existed. indicating viral usc
or an additional co-recep tor. CXCR4. These CXCR4-using variant viruses usually have
altered tropism and pathogenic properties. They arc common in late-stage subtype B
IIIV-1 infection, in which there is often a co-receptor switch from CC R5 to CXC R4 120.
2 11. II IV can thus be CC H5-ll'lI llie (H5), ( 'XCH-I-lro l li e (.1-1) or dual -mix trop ic: (H5-X-I) ,
1.1.3 Life cycle
The IIIV life cycle (Figure 1.1.3) begins with virus entry into the host cel l. Viral
gp120 binds to intcgrin u41J7. the gut mucosal homing receptor on periphera l T cells.
activa ting adhesion molecules to establish the virological synapse 1n I. gp120 binding or
Att achment/Binding
Cytoplasm
Export
Viral RNA Nucleus
___ sp l iced rnRNi\
mV~.~ ~~;~~ I~~dr~~e~Am RNA
Transcription
Preintegration
Complex
-- y~
Inte gration
lnt cgrasc r"
Figure 1.1.3 The Life Cycle of IIIV . The life cyc le o r IIIV begins with fusion o r the virus
particle to the host cell surfacc. jncdiutcd by the intcract ions ofgp l Zu. gp4 1. CD4 and CCR5
and/or CXCR4. A fter fusion , the vira l capsid and its contents arc released into the host ce ll
cytop lasm. Viral DNA is formed by reverse transcript ion ofthe RNA genome. Once formed.
the viral DNA is transported into the nucleu s and integrates into the host DNA. Upon
activation oft he cel l.The DNA is transcribe d to make new viral RNA. which will be used as
genomic RNA and to make new viral proteins. These move to the ce ll surface and buddi ng
begins. During maturation oft he viral particle. ind ividuallll V proteins arc released cleaved
and reassemble to [orm the matr ix. capsid. nucleocapsid. RT and iutcgrasc, completing
maturat ion ofthe virus particle. Ada pted from 123-25j .
CD4 induces a conform ational change in gp120 that allows interaction with ce R:> or
CXCR4 and allows gp-ll -mcdiatcd fusion to the host membrane 1261. Upon fusion. the
viral capsid is released into the cytoplasm 1271and the single-stranded (ss) R A genome
is released. The viral RT reverse-transcribes the ssRNA into a complemen tary ss
deoxyribonucleic acid (cssDNA) copy. The RT has R ase act ivity 12Xlthat degrades the
viral RNA during this process and has DNA-depe ndent D A polymerase activity 1291
that synthesizes a.l'l'II.1'l' strand li·omthe llllli.l'l'II.1'l' cssDNA to form a double-stranded (ds)
DNA copy ofthe Ill V genome. The dsDNA migrates to the nucleus and is integrated into
the host genome becoming an integrated provirus 1301.
Activation of CD4 ' T cells induces translocation of transcr iption fac tors NF" n
and NFAT to the nucleus 13 1. 321. which bind to promoter s in the viral LTR of the
integrated provirus and initiate transcription of the viral genome 1331. The lirst viral
transcripts. which encode several of the regulatory proteins. arc multiply spliced. then
exported and translated in the cytoplasm. Singly spliced and unspliccd transcripts arc
translated into the RT. intcgrase. viral protease and the structural proteins cuv
(po lypro ici n gp I( 0). gag. and ncr. The structural proteins Iorm the new virus panicle
around additional unspliccd transcripts that constit ute the IIIV genome. Afte r translation
of the viral proteins. the virus is assembled. gp l60 is cleaved into gp4 1 and gp l2 0 by
protcascs in the Ciolgi complex and transported to the plasma membrane 1341. The gag
and pol polyprotcins associa te with the IIIV RNA at the plasma membrane and budd ing
begins. During maturat ion of the viral particle. these polyprotcins arc cleaved and
reassemble to form the matrix. capsid. nucleocapsid. RT and intcgrasc, completing
maturation ult hc virus particle 1351.
1.1... Diagn osi s of III V in fecti on
Unless there is a high index or suspicion. Il lY infection is not normally diagnosed
immediately. Those infected may experience a flu-like illness (fever, headache, tiredness.
and enlarged lymph nodes) in the acute phase or infection. which usually disappea rs
within 1-4 weeks and is easily mistaken fix another viral infection 1361. l llV-iutcctcd
individuals arc highly infectious dur ing this stage due to the abundance or virus in the
peripheral blood and genital fluids. At scroconvcrsion. l ll v -spccific antibodies in the
blood can be detected by the enzyme-linked i rn munosorbcnt assay (ELISA) and Western
blot 1361.
The ELISA is generally used to screen donated blood products and for general
surveillance or infection 1361. II' the serum contains antibodies for specific Ill Y antigens
they will bind to the IllY uutigcn-coatcd ELISA plate. Because or the variability or this
procedure, the lack o r a comparable global standard and the concern or false positive
responses. a single ELISA test cannot he used to confirm Il lY infection, The Western
blot test, like the ELlS/\. is an antibody detection tl:stI 371. II' l ilV-spccifi c antibodi es arc
present in the serum they will attach to some of the Ill Y proteins on the membrane and
an image or bands will he displayed on the photographic film. A positive result is one in
which at least one viral band co rresponding to each gag. pol and cnv prote ins is present.
lfI cwcr than 3 bands are detected. the result s are inconclusive and another test is needed .
II' the person is recently infected (1-3 month s) a sufficient amount or antibodies
1'01' these tests may not yet be present. In this case. IIIV R A or DNA can be detected
using a polymera se chain reaction (PCR)-based method to confirm the presence or IIIV
genet ic materia l in the blood 136 1. This method . in quant itative Itm11. is normally used to
track clin ical progression o r IIIV infect ion and to monitor the effect o r antirctroviru l
therapy but can be used 10 confirm a new infection in high risk individuals. A high vira l
load is strongly corre lated to disease progression and increa sed risk o r transmission 13XI.
I IIV infection is con firmed when a sequence or tests. including a repeat or the initial
ELISA test combined with the Western blot test and PCR test for viral load. confirm IIIV
infection 1361.
1.1.5 Palho~cll csis
IIIV infects cells that express CD4 and CC R5 or CXC R4. part icularly C D4 ' T
cells. CD4+ T cells are key players or our immune system. They interact with the innate
immune sys tem and are requi red loractivation ofB ce lls and CT L. In the acute phase or
IIIV infection. there is an abu ndance or virus in the peripher al blood and genitai lluids. a
significant decrea se in the number o r circu lating CD4 ' T ce lls and a marke d increase in
antibody production and in the number or CDX+ T cells that recognize and kill IIIV-
infected cells. Followin g scroconvcrsion, when HlV-spccifi c antibodies are detect able in
the blood, the acute phase or viremia has passed and there is a rebound in the numbe r or
circulating CD4 ' T cel ls. During this asymptomatic period . Ill Y replication co ntinues
and the number or CD4 ' T ce lls gradually decl ines. When the number o r CJ)4 ' T cells
full s below 500 ccl ls/p l o r blood the symptomatic phase or infecti on hegins, marked by
the appearance or opportunistic inf ections and other symptoms. When l li v-inl cctcd
individuals become ill with one or more or the clinica l or indicator illnesses, they have
AIDS 1391.
The mechanism by which Ill Y causes C D4' T cell depi ction has caused much
deba te ove r the last fift een years. 110 ct al. 1401 showed that in the presence o r the
protease inhibitor ritonuvir, there was a rapid reduction in the amount o r free virus in the
plasma and a significant increase in the number or ci rculating CD4 ' cells. As drug-
resistant mutat ions evolved, the viral load increased and the numbe r or circulating CD4 '
cells decreased 140,411, suggesting that Ill Y causes CD4 ' T cell depletion by direct cyto -
pathic effect. Later. it was observed that African non-human primates infected with thei r
spec ies-s pecific strain or simian immunodeficiency viruses (S IYs) did not show
progressive CD4 ' T cell declines and manifestat ions or immunodeficiency despite
chronic viral replication 1421. Schindler ('{ al. 1431 reported that CD4 ' T cel l dep letion
was not observed in these hosts because ncr proteins from these SlY strains do wn-
regulate expression o r the T cell receptor (TCR)-CD3 co mplex leading to decreased ce ll
activation and apoptosis whereas nc r proteins from Ill Y-I and the chimpanzee strain or
SlY had no effect on TCR-C D3 surface expression. Th is suggested that increased
immune activation and apo ptosis leads to the dem ise or C J)4 ' T cc lls.
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Other mechanisms of IIIV pathoge nesis have also been suggested. cm~ ' T cell-
mediated killing of infec ted CD4 ' T ce lls has long been considered one of these
mechanisms 144.451but cytotoxic killing of infected CD4 ' T cell s may only be effective
durin g a certain " window period" of in fecti on 146. 471. Ce ll cyc le dysrcgu lation, caused
by chro nic T ce ll act ivat ion. acce lerated cell turnover and an imbalance in cytok inc
productio n. also leads to the dep letion of uuinlcc tcd CD4 ' and CDX' T ce lls by causing
perturbations in protein metabolism 14XI. Circulating CD4 ' T cells may also be
sequestered in secondary lymphoid organs 149 1. The relat ive co ntributions of eac h o f
these mechan isms on IIIV pathogenesis and CD4 ' T cell dep letion remain s unclear.
I. I.CJ l>ia:,:lIlsis llf AII>S
In Canad a. if ' an individ ual has received a positive result from IIIV testing and has
one or more of the clinical illnesses. or indicator diseases. such as pulmonary
tuberculosis. recurren t pneumo nia and invasive cervic al ca ncer. that person has AIDS
139 1. Symp toms of opportunistic i nfections com mon with AIDS include coma . extreme
fatigue, fever. nausea . vomiting. severe persistent diarrhea. vision loss. weight loss and
mental symptoms such as co nfusion and forgetfuln ess 1501. Kaposi' s sarcoma. caused by
the human hcrpcsvirus-S (I ll IV-X). is the most co mmon AlI)S- rdated cancer . It causes
redd ish-purp le lesions on the skin that were a hallm ark feature of AIDS patients in the
19X<)"s. Other op portunistic in fecti on s that can occur in AIDS patien ts includ e. but arc
not limited to candidia sis. toxoplasmosis. cytomegalovirus. herpes simp lex. l 'ncum ocvst is
[irovcci . tuberculosis and recurrent pneumonia 139. 501. In untreated Ill Y infect ion.
progression to AIDS takes about ten years on average. However. since the introduction or
antirctroviral therapy (ART). particularl y highly act ive ART (II AART ). progression to
AIDS can be delayed 1'01' several decades or completely prevented .
1.1.7 Antiretruviral therapy
Before ART was available. people with AIDS were unlikely to live 1'0 1' more than
a lew years. Since the introduction or ART in 19X7 1511 and IIAART in 19<)('1 521
mortality and morbidity in l IlVvinfcctcd patients has dramatically decreased 1531. ART
therapies have come a long way since they were first introduced. Antirctroviral drugs arc
more numerous. diverse with respect to antirctroviru l class. more potent and less toxic
than before, Current IIAART is a combination therapy consisting o r a cocktail o r at least
3 dif feren t antirctroviral drugs that belong to at least 2 di ffere nt classes or antirctroviral
agents. Currently. seven classes or antirctroviral agents exist. These include entry
inhibitors. CCR5 antagonists. nucleoside and nucleotide RT inhibitors (NRTls). non-
nucleoside RT inhibitors (NNRTls). protease inhibitors. intcgrasc inhibitors 1541 and
matura tion inhibitors 1551. Entry inhibitors interfere with the binding. fusion and entry or
the virus into the host cell. CCR5 antagonists bind to CCR5 blocking gp120 binding.
NRTls are modilied DNA nuclcotidcs that lack a 3" hydroxyl group. These arc
incorporated into the viral DNA during cDNA synthesis and result in DNA chain
termination as no addiiiona l nuclcotidcs can be attached to them. NNRTls bind directly to
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the RT and interfere with its ability to synthesize the IIiV eDNA strand from the viral
RNA. Protease inhibitors prevent cleavage or polyprotcins needed to produce infectious
viral particles while intcgrasc inhibitors block IIIV DNA integration into its host DNA.
Maturation inhibitors are still in development 1551. They could potentially inhibit proper
assembly of the virion and prevent maturation of the panicle .
Despite the eff ective ness or IIAART. many issues such as the generation oldrug-
resistance mutations. non-adherenc e, unwanted short and long-term side e ffec ts. cost, and
high pill burden exist. Non-adherence, due to poor access. drug abuse. pill burden. and
unwanted side effec ts, allows viral replication to rebound leading to the generation or
immune escape and drug resistance mutat ions 15(J-5l\1. However. in many regions where
individuals have access to state-of-the-art IIIV care. the incidence and risk or
antirctroviru l resistance and incomplet e viral suppression is declinin g 1591. Up until the
recent IIIV Prevent ion Trials Network (IIPT N) 052 randomized triall ()Oj. it was thought
that even while l llV-infcctcd individuals had IIAART- suppre ssed viral loads. they were
could still pass the virus on to others. However, results oft he IIPT N 052 trial showed that
early initiation or ART is efficacious in preventing IIIV transmission 160. 611.
I.I.N Viral persistence
Despite effect i ve therapy. IIIV persists and continue s to infect new hosts.
particularly in areas where ART is unavailable or treatment s are not initiated early in
infcciton. IIIV persistence is mainly due to the number o r mutations that can be generated
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in minimal time periods and to its ability to maintain latent inf ecti on as a provirus. The
viral RT lucks proofreadin g capacity allowing a high error rate and multiple mutation s to
occur 162/ thus leading to the rapid development of viral quasispccics including drug-
resistant and immune escape variant strains. In some cases. a single mutat ion can confer
resistance to some drugs 1631. while a sequential accumulation of multiple mutation s is
required to confe r resistance lorothers 16-11. The mutations generated in the presence of
one drug may lead to cross-resistance in which the virus becomes resistant to drugs to
which it has never been exposed 165. 66/ . This usually co n fers resistance within one class
of inhibitor but is of great concern as it significantly limits the combinations of ART il uu
can be used. However. in regions where state-o f-the-art ART is avai lable. these problems
1.2 C DIl+T ce lls
Hematopoietic thymocyte precursor cells that migrate from the bone marrow to
the thymus mature there and become T cells. Both CD4' and CDX' T cells mature in the
thymus and are distinguished trom each other by the expression of their respective co-
receptors (CD4 or CDX) and by their d i fferen t e ffe cto r functions. CD4+ T cells are
div ided into several subgroups ( I'll L T1I2. T1117. T,cgs. ctc.) based on their diffe rent
cyioki nc product ion and effec tor functions. Act ivated CDX' 'I' cells (CTL) kill virus-
in fected and tumor cells. The fo l lowing section will address many aspects of CDX' 'I' cell
development and function including how these cells recognize antigen. how they develop
in the thymus. and most importantly their role in IIIV in fection,
1.2.1 Th~ T cell receptor (T CR)
Each T cell has - 30.000 clonotypic TCRs on its surface 1671. Two d ifferen t TCR
hctcrodimcrs. the u:11TCR and y:i) TCR exist. The u:11TCR. the 1•ocus of this section. is
expressed on most T cells and is homologous to the antigen binding fragment (Fah) of
immunoglobulin (Ig) 16XI. The y: i) TCRs represent a minor subset of TCRs. which have
di ffere nt antigen- recognition propert ies from the u:fl TCRs. Each TCR consists of two
receptor chains. which are disulphidc-linkcd variable trans-membrane glycoprotcins
anchored in the membrane (Figure 1.2.1). The membrane proximal region of each chain
is termed the constant region (C). while the membrane dista l region of each chain is the
variable region (V). The amino-terminal variable region is the site of antigen binding.
Crystal structures of the u:11 TC R 169-731 haw revealed that all but the Cu
domain of the TC R are similar in structure to the domains of Igs. The lg-likc domai ns of
the TCR are constructed from two II sheets linked by disul fide bridges to form a II barrel.
Four loops of [I strands at the outer edge of the II barrel (on n the hypcrvariablc regions of
the V region or each chain. These loops form a complementary surface to a particular
antigen and as such are called complementarity-determining regions (CDRs). The C«
domain diner s lrom the others in that hal l' o r it is connected to the C]] domain limlling a
IIsheet while the other hal I'is composed or loosely packed strands joined to an u-hclix by
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achain ~ chain
Variabl e Regio n (V)
ConstantR egio n(C)
TransmembraneR egion
• Carbohyd rat e -ss- Disulph ide Bond
F i!-: lI r~ 1.2.1 The s tr uctu r e of the u:ll T CI{. T he TC I{ is composed of two
transme mb ra ne gp chai ns, u and II. Th e memb ran e pro xim al reg ion of the ex trace llula r
portion or each cha in is termed the co nsta nt reg ion (C ). wh ile the membrane di stal region
o ft he ex trace llu lar po rtion o feac h chai n is the var iable reg ion (V) . T he ami no- tcnui nnl
va riable region is the si te o r antigen bindin g. Both cha ins a re an chore d in the me mb rane
via a sho rt sta lk seg ment. T his seg ment co nta ins a cystei ne res idu e tha t Ion us a disul fide
bond, linkin g the two chain s . T he hydroph ob ic transmembr an e segment o r eac h cha in
co nta ins positi ve lycha rged res idu es. Ad apted rrom1 741.
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a disulfide bond . Gene rcarrangcmcms, j unction diversity and rando m pairing o r u and 1\
chains result in high variability orTCRs. part icularly in the highly variab le CDR] region
that interac ts direc tly with the antigenic peptide, CDRI and CDR2 arc less variab le as
they arc requ ired 1'0 1' interac tion with sclf-Ml LC molecules and thus. must have conserved
regions to maintain recognition 16XI.
1.2.2 Peptide processing and Inadin~ nntn Mile cla ss I
CDX+ 'I' cells recognize peptid e antigens through the TCR only in the co ntext or
self major histocompatibil ity complex (Ml K') class I molecu les (human leu kocyte
antigens (lIL A) in humans). MIIC class I is expressed on nearly all nucleated cells as
well as plate lets, During the inflammatory response. cytokincs such as IFN-y and tumor
necrosis factor (TNF)-u increase the expression o r MIIC class I molecule s on the cell
surface, The majority or the pcptidcs presented by MIIC Class I arc de rived from newly
synthes ized proteins in the cytosol a lthough a smaller fraction is derive d from uuuurc
proteins 175. 76 1. These protei ns arc degrad ed through the proteolytic activity o r the
protcasomc, a cylindr ical structure formed by the adenosine triphosphate (ATI')-
dependent association o r the proteolytic core parti cle and the regulatory partic les that
make up the base and the lid 1771.
The protcasomc exists in two forms: I ) The co nstitutive protcasomc. which is
present in all somatic ce lls and 2) the immunoprotcasomc, which is present only in
antigen-presenting cells (AI'Cs) and inflame d tissues. Whcn AI'C arc stimul.ucd with
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IF -yo the low molecular protein ( I.M l') 2. Uvl1'7 and multi catalytic endopeptidase
complex subunit (ME CL)- l o r the immunopro tca somc are synthesized. These re place
con stitutive subunits in the newly syn thesized prot casorn c 17XI. The A'lP<dc pc ndcnt
activity or the immuno protcaso mc is regu lated by I'A2X. which binds to the terminal
rings or the protc asom c to form a prot ease-act ivat or co m plex that opens the pro teol yt ic
core part icle. strongly regu lat ing the degrad ation and release or endogenously-
synthesized pcp tidc s 1791. The o ligo pcptidcs released range from 4-20 ami no ac id
residues in length and terminate mostly with basic and hydrophobic residues, Suc h C-
termin i are favou red Ill!' uptake by the transporter associated with antigen processing
(TA P) and are required Ill!' binding 10 MIIC class l molcculcs 17XI,
Once released lr om the protc asom c. the major ity o r the pcpt idc s are furth er
degraded III I' use in protein synthes is or energy production. The remaind er bind to
chaperone s. whic h protect them Irom dcgradarion until translocation into the lume n o f' the
endoplas mic re tic ulum (ER). Transport into the ER is ac hieved in an AT I'-depe l1lknl
man ner by the heterodim cric TA P compl ex, an integral ER mem brane protei n " hose
expre ssion is sig nifi ca ntly en ha nced in the presence or IFN-y IXOI. The TA P co m plex
preferentially transports pcptidc s X- 16 residues in length, with pcptides o r the appropriate
length Ill!' bind ing to !'vII IC class I (X-I I residues) most effic iently transported . Once
inside the ER. pept ide precursors that arc not at the appropriate MIIC class I-bind ing
length are trimmed at the Nstcnn inus by the ER aminopeptidase associated with antigen
pro cess ing (ERAA I') to generate pc pt idcs that ca n be presented by MIIC class I lXII,
MIIC class I mo lecules are synthesized and loaded with peptid e in the ER. This
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process is mediated by several molecular chaperones such as culncxin and culrciiculin.
which prevent degradation of properly fo lded proteins and allow stable assembl y of the
MIIC class I: peptide complex (pMII C). ER-resident proteins. including ERpS7. the
TAP-associated glycoprotein (tupasin). and the TAP hctcrodimcr interact with the newly
formed complex. 'la pasin. which has an ER retention signal in its cytoplasmic domain
IX2j . mediates the critical interaction of the MIIC class I hctcrodimcr with TAP. allowing
peptide binding IX]I. Alle r transport into the ER via TAP. pcptidcs are loaded in the (11(12
domain of MIIC class I molecules. Low affi nity pcptidcs do not cause the release of the
MIIC lrom the peptide-bind ing complex (I'BC). while high affi nity pcpiidcs may cause
conformational changes that complet e the fold ing of the MIIC class I molecule resultin g
in its release from the I'BC and subsequent display at the cell surface IX4j.
Each individual carries a set of (, classical MI IC Class I allele s: one A. one B and
one C allele from each parent. These alleles are highly polymorphic. particularly in the
amino acids forming the peptide-bindin g groove. Such polymorph isms are likely the
result of evolutionary pressure to maximize peptide binding diversity in the presence of
multiple emerging pathogens. lach MIIC class I molecule has a preferred peptide-
binding moti f: however . with the lack of structural data these are not all known . All.
however. are functionally com plex: they interact at different sites with peptides.j 12-m. the
(1:11 TCR. the CDXcorcccptor and natural killer cell (NK) inhibitory molecules IXSI.
I')
1.2.3 Peptide recuguitiun and activatiun uf C DS+T cells
MIIC class l molcculcs present pcptid cs in the peptide binding groo ve. formed by
two flanki ng u-hcliccs and a 110 01' ofantiparallcl jf-strunds IX61. Peptide anchor residues
interact with the MIIC class I binding cleft in specificity pockets through a series or
hydrogen bonds and ion ic interact ions leaving the upward poin ting side chains availuhlc
till' interaction with the TCR IX7. XX I. Normally. MIIC class I presents autologous
pcptidcs de rived by degradat ion or de fective riboso mal products (DRiPs) and mature
protein s that have reached the end or their natural life. Since T ce ll precursors that
recogn ize sclf-pcptidcs arc elimin ated in the thymu s. the presentation o r these autologous
pcpt idcs by MIIC class I is typically ignored by T ce lls. In contrast. T cells bearing
receptors that recogn ize foreign pcptid cs bound to sclf-Ml K' class I mature and arc
highly specific for fore ign ant igens in the context ofsc lf-Ml fC IX91.
The TCR alone allows til!' pcpt idc/Ml IC (pM IIC) recognition but is not sufficient
for intracellular signalling. Other molecules. CD3y. C D3b. and C D3l: (C D3 complcx) and
the TCR~ chain . which con tain conserved immun orcccp tor tyrosine-based act ivat ion
motifs (lTAM s). arc requ ired till' the expre ssion or the TC R on the surface or the ce ll and
till' the signalling cascade that follo ws antigen recogniti on 190-921. The interaction o r the
TCR comple x (TC R and CD3 complex) with pMll C is stabilized by the cm: co-receptor
on CDX' T cells 1931. pMl lC recog nition by the TCR enhances lymph ocyte-spec ific
protein tyrosine kinase (Lck) recruitm ent to the TCR complex 1941. l.ck phosphorylatcs
the ITAMs or the CD3 chains and the TCR~ chain. which allows the ~-c ha i n -assoc i a t ed
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protein kinase 70 (Zap-70) to bind . ZA P-70 is then phosphor ylated by l.ck initiating an
intrace llular signalling cascade involving many other protein s that ultimately result s in
cytokinc production, proliferation , diff crcntiar ion and/or activation-induced cell death
IlJ5. lJ61. This pro cess is also dependent on costim ulatory receptors such as CD2X IlJ71
and other auxiliary adhe sion molecul es such as intcgrins IlJXI.which allow formation or
the immunol ogical synapse. CD2X is expressed on T eelIs and is ligated by B7 on APCs.
This ligation provides an essential co-stimul atory signal that promotes TCR-indue ed
tyrosine phosphor ylation o r the TCRS chain and ZAP-70. which increases T cell
pro li feratio n by augmenting IL-2 product ion and prevents the induct ion o r ancrgy and
cell death,
Once activa ted through this mechanism. C DX+T cells become effector e n . CT L
me diate cytotoxic killing o lvirus-infcc tcd and tumor ce lls through two dominant contact -
depend ent mechanisms: g ranule cxoc yto sis and the recept or-mediated Fas-Assoc iatcd
prote in with Dcath Domain (FADD) pathw ay (rev iewed in IlJlJJ). Activation or C()X' T
ce lls results in the uprcgulat iou or cytokinc recept ors and induces the expressio n or
granule components such as pcrf orin and granzymcs (seri ne prete nses). Perform is a
C} t-dcpcndent pore-forming protein that rnultimcri zcs in membran es and is responsible
1'0 1' the entry o r g ranzy mcs into ta rget cells. however . the mechanism by which this occurs
is unclear 1100I. Granzymc s A and B are the most abund ant grunzytuc» and are each
capable o r protcolyti cally act ivating cell death pathw ays. which ultimatel y cause
fragm entation o r the target cell' s DNA and subsequent cell death IIO\. 1021. The perf orm
pathw ay is the predominant pathwa y used for C'I'Ls u cd ia tcd kill ing or target cells likely
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due to its efficiency. Cytotoxic granules arc released within minutes or target cell
recognition and can he reoriented after each encounter allowing C'lLmcdiatcd killing or
multiple target cells 11031. The FADD-mcdiatcd pathway which includes membe rs o lt hc
T F receptor pathway. T FRI. TRAILR and most common ly Fas 1104-1061. is also
involved in C'll .vmcd iatcd killing o r target cells. However. unlike in the granule
cxocytotis pathway. very lillie ligand (c.g, Fasl.) is stored and so there is a greater lag
time (1-2 h) between recognition and killing of each target cc11 1991. Activation or this
pathway relics on the release of' certain ligands (c.g. Fasl. ) which bind to their receptors.
resulting in the recru itment or FADD and caspasc X. This leads to the activation o r a
cascade or protcascs, part icularly caspascs. which then cleave various substrates
responsible 1'01' the changes associated with apoptosis such as nuclear membrane
breakdown and DNA cleavage 11071.
1.2A Tcl'I l sc lccliun
Tccllsarc derived from hematopoietic stem cells in the bone marrowthat migrate
through the blood to mature in the thymus. a lymphocpithcl ial organ in the upper anterio r
thorax II OXI. Maturation requires the stepwise completion of several processes includin g
rearrangement or TCR genes, tornuuion or a complete TC R. and positive and negative
selection that ensures sclf-Ml IC restriction and self-tolerance (Figure 1.2.3) 11091.
Tolerance is the state o ri mmunological nonrcsponsivcncss in the presence or a particular
antigen. It is achieved through the deletion of autorcuctivc T cells dur ing matura tion
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Fi!-:ure 1.2.2 Positive and ne!-:ative selectio n in the thymu s. C D4/C DX doub le positive
(DP) thymocytcs undergo TCR gene rearran gem ents in the co rtex. DP ce lls ex press ing
appro priate TCR s receive a " rescue s igna l" th rou gh the sei r-pM I IC:TC R inte ract ion with
cor tica l thym ic epithe lial ce lls (CTE C) . w hich indu ce s DP maturat ion to the C D4 ' X- o r
C D4-X' sing le positi ve (S P) stage. while ce lls ex pres s ing TC Rs that lack specificity III I'
sc ll-M l K' unde rgo apo ptos is . Posit ivel y sel ected ce lls enter the medulla . In the med ulla.
high -av id ity TC k /sc lf-pc ptidc .M l lt. ligations with medull ary th ymi c epithelia l cel ls
(M T EC) or DC lead s to negati ve selection o r se lf-reactive thymocytc s . Adapted fro m
11 091 ·
23
(ce nt ra l to lera nc e) and the suppress io n o r auto rcac tiv c T cell s that ha ve escaped
el iminatio ni n thc pcriphcry( pcr iphcra l lolerancc) .
On ente ring the thymus. immature lymphocyte s commiucd to the thymocyte
lineage interact with the thym ic stroma in the cortex and bcgin differentiation along the T
cel l linea ge pathway. At the end or this ph ase (- 1 week ). the th ym ocytcs e xpre ss
distinct ive marke rs or the T cell lineage such as C D2 but do not express markers o r
matu re T cell s (CD]. CD4 or C DX). Th ese ce lls arc called doub le-n egat ive (DN)
thymocytcs because they lack CD4 and CDX. The DN phase is furthe r subdivided into
tou r s tag es (DNI. DN2. DN] and DN4) based on the pre sence and ab sence o r certa in
surface mol ecul es and the sta te or TCR chain ge ne rearrangem ent 11101. II' ge ne
rcarrungcmcut o r the [I chain locus is unsuccessful in the D ] stage. the cells die by
apoptosi s . Success fu l ge ne rcarrun gcmc nt result s in the ex press io n or a co m ple te pre -
TCR. a com bination or the II chain and a surrog ate prc-Tf.R u chain. at the ce ll surface
1110 1. The ce lls then en te r the D 4 stag e in which prol ife rat ion occ urs . Th e asse mb ly or
the prc-TtR with the CD] molecule s arrests furth er I~ chain rearrangement and leads 10
the expre ssion ofboth CD4 and CDX on the cel l surface. When these do uble positive
(DI') thy mo cyte s cea se to proliferate . the u chain locus rea rra nge s and a co mplete u:11
TCR is prod uced.
The fate ofeach DI' cell depend s on the abilit y or its ncw Tf.R to interact with a
sei r-pMIIC complex, a process know n as positive se lec tio n, This process occ urs in the
co rtex ofthe thymus and is mediated by cort ical thymic epit he lia l ce lls (CT EC). Receptor
ed iting, in which sequential rounds or rearran gement at the TeR u locus occ urs. at this
stage increases the likelih ood or success ful sel f-Mi ll' restriction 11111. 1)1' ce lls
expre ssing appropriate TCRs receive a " rescue signal" through the scll:'pMl ll' :Tl' R
interaction. which induces DP maturati on to the coas or CD4-X' single positi ve (S P)
stage 11121. while cells ex pressing TC k s that lack speci fici ty 1'0 1' sclf-Ml IC (- 95'1.,)
undergo apoptosis 11131. Chcmok incs that direct the T cell for further matur ation within
the thymic medull a arc also produced dur ing this time 11141. Nega tive se lec tion, in which
cells ex pressing high av idity sell-reactive TCR arc del eted , occurs throu ghout thymic
development 11151. but is mostly conccmratcd in the medulla 11111. In the medull a. this
process is dependent on the high av idity 'l'Ck .scl f-pcpridc.scl f-M l l'C interaction and
costimulatory signals [rum APe.. particularl y the interaction or CD2X (on thymocytcs)
and 137 (on DCs) 1110. 1171. Other costimulatory signals through CD40 provided by
medullary thymic epithelial cells and DCs IIIXI. and through CDS and C D43 on T ce lls
11191 also have a role in clonal deletion , Nega tive selection occ urs to a lesser extent in
the thymic cortex. where there is a lack or costimulatory APCs. l lcrc, clonal deletion o r
scmimaturc T cells with strong TCR binding in the absence o r costimul .uion is Fas-
dcpcndcnt l l Ztl],
In order 1(11' successful clonal deletion or potenti ally sel f-reac tive T ce lls to occ ur.
there must be a complete rcprcscnu nion or sel f-antige n within the thymus. The
ex pression or many of these tissu e- spe cif ic antigens in the thymic medull a is controlled
by genes such as the autoimmun e regulator (A IRE) gene 11211. AIR!::deficiency in mice
and in humans result s in autoimmunity. highl ightin g its importance in clonal deletion and
centra l tolerance 11221. II' a cell is tolerant to tissu e-sp ecific antigens and survives both
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positive and negative selection. it leaves the thymus and circulates in the periphery as an
immunocompetent single positive (SI') mature 'I' cell. This means that selection of the 'I'
cell repertoire is based on the recognition of one or a few sclf-Ml K' molecules modi lied
by the binding of a vast array of sclf-pcptidcs. Thus. the recognit ion of sclf-pcptidcs
below a certain threshold of avidity is ultimately responsible for positive selection 01''1'
cells. The diverse repertoire 01''1'cells that is selected recognizes foreign pcptidcs bound
to the same sclf-Ml K' molecule as the selecting sel f-peptide in the periphery. This means
that foreign pcptides that arc recognized in the periphery arc actually all hctcroclitic
variants of sclf-pcptidcs, l lctcroclitic variants arc slight alterations of naturally-occurring
pcptidcs that enhance TCI{ recogni tion 11231. We will apply this concept to generate
potentially hctcroclitic variants of IIIV pcptidcs for possible usc in therapeutic vacci nes
(discussed further below).
1.2.5 ens' Teell response in IIIV infection
Several findings suggest an important role for CDX' 'I' cells in controlling IIiV
infection. Studies by both Koup £:1 al. 11241 and Borrow £'1 al. 11251 indicated CTL
control of IIi V replication during acute infection by monitoring the level of l llVvspcci fic
CTL activity in relation to plasma viremia in l llV-infcctcd study participants. In both
studies. participants who showed an increase in CTL activity duri ng acu te infection
showed a concomi tant dec line in viremia. whereas those who had low or undetectable
CTL activit y had prolonged symptoms and persistently higher levels of viremia. CDX' 'I'
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cel l-mediated contro l or l ll Vvi nfcct ion was also suggested [rom ill " i l'tl CDS· T cell
dep letion studies in the SIV rhesus macaq ue (S IVmac) model or AIDS. These studies
showed a rapid and markcd increase in viremia in acute 1126. 1271 and chro nic Il nl
iulection when C DS· 'I' ce lls \ \"CIT eliminated . l lowc vcr, upon the reappearance or SIV-
spec ifi c CDS· 'I' ce lls. the increase in viremia was suppressed 11271. The rapid generation
or sequence mutat ions with in inun unodo minant CT L cpiiopcs 112S- 1321 provides
additional evidence o r CTL pressure on II IV replic at ion as does the association or
particu lar l ll.A class I alle les (Bn and BS7) with long term nonpro grcssio n (rev iewed in
IIJ 3. IJ 4i) .
Long-term non-progrcssors (LTN l's) ex hibit natural immun e control to IIIV
which allows stable normal CD4· 'I' cell counts and continuous low 10 undetectable viral
loads. Because or the lack or an animal model or protectio n. studies or LT I's and IIIV-
expo sed but unin fcctcd ind ividuals (EU) have been used to define correlate s or
protecti on . Whi le vigoro us C DS· 'I' ce ll respo nses have been implicated in the
mainten ance or low viral load in 1.'1' I's IUS . U61 and seronegativity in EU IIJ 7-IJ91 .
no single CDS' 'I' ce ll function has prove n 10 co rrelate with protection or control. LTNl's
do. however, possess a greater proport ion or polylun ctionul l ilVvspccific CDS· 'I' ce lls
relative to l ll v- infcctcd progrcssors 11401. HlV-spcc ific CDS· 'I' ce lls from LTNl's can
release several cyto kincs simultaneously (IFN-y. 11.-2. TNF-u. mq, inflam matory prote in
(1'v1 11')- 1I1.and pcrforin ) 1140. 14 11. have greater prolifcr.uivc capacity 1142. 1431 and
have the ability 10 dranuu ically uprcgulate grunzymc B and pcrforin product ion nltcr
long-term culture 144.1 441.
Other specific properties or CDX+ T cells have been proposed as correlates or
protective immunity in LT Ps and IIIV controllers. Chen et (/1. 11451 round that 111.1\-
B27-restric ted CDX' T cells in controllers were better able to inhibit viral replicatio n
through targeting or the immunodom inant Gag cpiiopc . This was also associated with
distinct TCR clonotypcs, characterized by superior control or IIIV- I replication in vitro.
greater cross-react ivity to cpitope variants and enhanced loading and del ivery of pcrforin .
Similarly. Turnbull ('( al. 11461 have shown that cpitopc-spccific responses with enhanced
cross-recognition or sequence variants were most strongly corrclurcd to delayed
progression to disease, They also reported that the rate or disease progression is
dete rmined by the quality or responses to certain critical epitopesand that this is
influenced by properties or the dominant TCRs used 1'01' cpitopc recognition.
Importantly. 11.-2 production by polyfunctional HlV-spcci fic CDX' T cells has also ken
correlated with enhanced viral suppression 11411. Almeida ct (/1. 11471 reported that
polyfunctionali ty and potent l ll v- suppressivc act ivity or l Il v- spcci fic CDX' T cells arc a
result or increased antigen sensitivity. while Ilarari ct al. 114XI argue that CDX' T cel ls
with these att ributes arc equipped with low-avid ity TCRs and thus have low ant igen
sensitivity. Such debates must be resolved in order to properly de fine CDX' T cell
correlate s o r protection. It is important to note as well that CDX' TCl:lI responses may not
he the only protective measure in IIIV protect ion. Emu ('( al. 11491 compared 111.1\
polymorphisms and l ll v -spccific CDX' T cell responses among LTN l's. non-cont rollers
(high level viremia), and "ART suppressed' individuals (undetectable IIIV RNI\ while
on I\ RT). In this study. while the majority or LTNl' s did have higher III V-specilic CDX'
'I' cell responses than the other group s. man y 1.'1' Ps lacked protective l ll .A class I
allele s and evidence 01''1'cel l-mediated control. It is. however. importan t to note that on ly
gag. env and pol peptide pools were used to detect CDX' 'I' cell respon ses, Thu s it
remains possible that these individual s have detectab le CDX' 'I' cell respon ses to other
IIIV proteins.
Defining how CDX' 'I' ce lls inhibi t IIIV is one or the most critic al question s that
need to be addressed in orde r to develo p efficacious protect ive and therapeutic vaccines.
In addition. we must also determin e which CDX' 'I' cells arc responsible for viral co ntrol.
Seve ral subsets or CDX' 'I' cells includ ing naive. effec tor and memor y. exist. Upon
activation. naive 'I' ce lls beco me eff ector 'I' cells (CTL) or di ffc rc nti. uc into a diver se
array or memory 'I' ce lls, The process by which a naive cell enter s into an effector lineage
or memory lineage is not enti rely clear. Chang et al. 11501 show that a div iding 'I' ce ll
initially responding to a microbe asymmetr ically divides into two daughter cell s each
with a d ifferent cell rate specification: a terminal effector lineage and a memory lineage ,
Sarkar ct al. 11511suggest that cell s that receive prolon ged antigenic stimulation durin g
the later stages o r infect ion are more likely to become terminally differentiated effe ctor
cells. while those who do not endure prolonged antigen stimulation and have the ab ility
to make 11.-2 beco me memory 'I' cells, Perhaps both o r these mechan isms arc involved or
maybe the memory phenotype depends entirely on the antigenic history or each 'I' ce ll.
CTLs produ ce effec tor molecules. such as pcrforin and granzyme B. and arc
responsib le tor the targeted dest ruct ion or virus-infected or tumor ce lls. They arc
terminally different iated and short-lived. although 5- 10'% or these cell s survive long-term
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and can be reactiva ted 1'01' protection upon reinfection with the same pathogen 1152.1 5]1.
Memo ry T cells diff er from both naive and eff ector T cells and can he further subdivided
into effec to r memory T cells ( TI ~!) or central memory T cells (Tn !). These memor y T
cell subsets arc defined by location. funct ion and phenotype. Tl' ~ l arc long-lived cells
that. upon each ex posure to their specific antigen. generate an accelera ted immune
response. They ex press CD62L and CCR7. which allows them to cross high endothelia l
vcnulcs (1IEVs) and enter the lymph nodes from the bloodstream 11541. Tl ' ~ 1 produce 11 .-
2 which allows them to sustain their own survival but arc poor produccrs ofc ffcctor
cytokines, such as IFN-y.until they arc reactivated 11551. TI~ 1 arc shorter-lived. reside in
non-lymph oid tissues and expre ss low levels or cytotoxic effec tor molecule s such as
granzymc B and perforin 1155. 1561. 1\ study by Freel ct ul. 11571 that investigated the
ability ofcells from vario us differentiation stages to inhibitlll V replication showed that
early memory stages through termin al e ffec tors were able to e ffectively inhibit vira l
repl icat ion [0 similar degrees. Howe ver. given the strong correlation between the
susta ined presence or I ll V-spccific cus' Tn ! and long-term non progression 115li. 1591.
it appears that cos' Tn ! arc vital to III V con trol and as such should be a target o r both
therapeutic and prophylact ic vacc ines.
I .J Thcrupcutic vaccincs
Two genera l classes or vaccines exist: preventati ve vaccines and therapeutic
vacc ines. I'reventati ve vaccines are admin istered to uninfcctedindi vidualstoprovide
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protection against future infec tion . These vaccines ofte n consist of live attenuated or
inactivated microorganisms. or parts of those microorganisms. that stimulate the body' s
immune system and prime immune cells to respond quick ly against subsequent i n fec tio n.
Preventa tive vacc ines arc effec tive because of immunological memory. which allmvs the
adaptive immune system to easily recognize and destroy pathogens it has already seen,
Preventative vaccines arc available fix a number viral in fections 11601 and arc
responsible for the global eradication of smallpox 11611 and ncar eradicat ion of
poliomyelitis 11621.
Therapeutic vaccines. unlike preventat ive vaccines. modulate the ongoing
immune response in unresolved or chronic conditions. They typical ly induce cell-
mediated immunit y rather than antibody- and complement-media ted immunit y (altho ugh
some vaccine initiatives aim for neutralizing responses) by enhancin g existing or
generating new immune responses towards chronic pathogens or tumor antigens.
Therapeutic vaccinat ion can be achieved through both passive tra nsfer and active
immunization to selectively reduce immunopathology. Thei r potential usc in IIIV
in fect ion and mechanisms by which all effective therapeutic IIIV vaccine may be
designed arc discussed in the following subsections.
1.3.1 T he need for a therapeutic IIIVvaecine
For II;\ ;\ RT to be e ffect ive , strict adherence is required . Initially. II;\ ;\ RT
regimens significantly impacted daily life as special dietary and strict scheduling
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require ments were demanded in order to prevent the development or drug-resistance
mutations 156. 65. 66 1. owadays . many drugs can he combined into a single pill. which
reduces pill burden and scheduling requ irement s. l lowcvcr, not a ll combinations or drugs
arc avai lable in this single dose. therefore , i f a person de velops several drug-resistance
mutat ions they may have to resor t to harsher IIAART regimen s. IIAART is also very
toxic and even short-term usc is associated with the l ll v -associatcd lipodystroph y
syndrome 11631. and cardiovascular and bone disease 11 6~ I. Therapeutic vaccination
would reduce the need tor toxic and expensive ART and would o ffer several adva ntages
over current ART such as fewer short- and long-term side effec ts, longer last ing effec ts
following a single administration. and a reduction in the number or ART-resistance
mutations. Previous and current c linical trials suggest that the side effects assoc iated with
therapeutic vacc ination wou ld be similar to those o r approved vacci nes, such as
inflammat ion at the site o r injection and mild flu-l ike symptoms 1165 1. The ultimate goal
or a therapeutic vacc ine would be to generate an anti-I IIV immune response that would
complete ly clear the infection. howe ver. most resea rchers think this is not possible in
IIIV infect ion due to the virus' ability to remain laten t for deca des 11651. An e ffec t i ve
therapeutic III V vacci ne could. howeve r, prevent or delay the need II II' ART by
sustaining immu nologica l fitness and the level and stability o r C l)~ ' T cells. thus
allowing viral control without the added toxicity or ART.
While much research has been directed at therapeut ic vaccination. there is no
therapeutic vacc ine app roved for human usc II Mll . Several challenges lace the
develo pment o r an eff ec t iv e therape utic IIIV vaccine. The virus' ability to proliferate
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quickly and remain quiescent for many years desp ite CT L pressure means a therapeutic
vaccine co uld help contro l the infection but will never clear it. Also, due to the variation
in IIIV stra ins and limited resistance to closely related strains. a universal vaccine is
unlikely, The disappoin ting MERC K Step trial I J 671. althoug h a preven tative vacc ine
trial. len us with two important questions that need to be answered fill"effective vacci ne
design - J) Whic h CTL funct ions correla te with protection'! 2) What magn itude o r
response in assays correla tes to an e ffec t ive CT L response in vivo'! A nswers to these
questions will allow us to surpass current challen ges and design better future vacc ines,
1.3.2 Pcptidc-h ascd vac cines
Severa l approac hes to therapeutic vacc ination for IIIV infection have been and /or
arc curren tly being exp lored, These include the usc or whole inact ivated IIIV IIMq.
recombinant D 1\ and viral vectors 1169- J 7 J I. dendritic cell s 1172-1741.protein subunits
and pcpt idcs 1175. 1761. Peptide-based vaccine s. specifically cpitopc -bascd peptide
vaccine s. arc or particul ar interest becau se they allow the abi lity to select the mini mal
immunogenic region or specific protein antige ns that can be targeted by a specific ce ll
type (primarily CT L) to induce e ffec tive and precise immun e responses. l'cpt idcs arc
produced eas ily and safe ly, therefore, can be produce d on a large scale. and quite
economica lly. II' injected . pcptidcs cannot revert to a virulent form or integrate into host
DNI\ . conce rns assoc iated with live and attenu ated vaccines and DNI\ vacci nes.
respec tive ly. Pept ide-based vaccines can also be designed to contain multip le cpitopcs or
one or more patho gens. which. given the II l.Avrcstricti on or the cpitopcs. is a necessity iI'
a broadly appli cable vaccine is desired . Broad vaccinat ion strategies should also include
the incorporat ion or pcptidc s that elicit immune respon ses across a variety or IllY clade s.
which may be achieved by basing pept ide design on conserved regions in virus strains.
One such strategy is the use or mosaic vacc ine strategies which use a computational
approach to design polyvalent T cell-based vacc ines 11771. This strategy maximizes
covera ge o r cross-clade IllY sequences .
Although there are many adva ntages to peptide-ba sed vacci nes. there are also
many challenges . Such vacc ines must take the presence or B and T ce ll cpitopc s and
l H.Avrcstriction into consideration. In cance r immunotherapy. appro aches such as the
Tubingcn approac h 117XI. which combines gcnornics. pcpt idomics, bioinform atics and T-
cell immunology. allow the idcmific.uion . se lection and validation or large numbers o r
MII C/lIL A class l-associatcd pcptidc s from tumor-associated antigens 1'01' use in
vacc ines. Peptid e stability. delive ry and low immun ogcnicity also pose difficulties in
genera ting e ff ective pept ide-based vacci nes but these may be overcome through peptide
modificat ion. Peptid e stability can be improved through the incorporati on or II-amino -
ac ids into the cpitopc, which increases MII C-bind ing affi nity and allows protease-
resistance 1179. I XOI. and through modi fications or the amino and carboxy termin i. which
also allow protease- res istance and improve the enzymatic stahility or the pept ide II XII .
Peptide del ivery strategies have been significantly improved throu gh the use or
recom binant cytokinc adj uvants IIX 2. IX] I. oi l-emulsion-type adju vants IIX41 and recent
deve lopments in Iiposomc .uni crop articl c and nanop articlc deliv ery sys tems (reviewed in
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II XSI). Impro vements in del ivery result in enhanced immun ogcnicity. hu munogcn icity
can also he improved through slight cp itopc modifi cat ions. in which one or several amino
acids arc substituted with others. l lctcroclit ic pcptidcs. which arc the IllCUS o f this
rcsca rchprojcCl. rcprcscnta napproac h toc pitopc moditicat ion.
1.3.3 IIctcmclitic pcptidcs - their IISC in therapeutic canccr vaccines and potential
use in therapeutic IIIV vaccines
The term hctc roclitic is defined as "deviating from ordinary form s or rules·· I IX(l l.
l lctcrocl itic pcptidcs arc slight alterations of naturally-occurr ing or index pcptidc s that
enhance TCR recog nition 1123 I. They do not ju st deviate from the index pept ide in terms
ofsequence but deviate from the index peptid e in terms of thei r funct ional ity. l lctcroclit ic
pcptidcs stimulate more potent immune responses aga inst their respective index peptide
than the index peptide itscl fllX 71. To date, this phenomen on has been employed most
effectively in therapeutic cancer vaccines to overco me suboptimal MI IC/Te R affi nities
and T cell tolerance to tumour -associated antigens IIXX-1911. Tumour-a ssoc iated
antigens arc generally self' ant igens that become overcx prcsscd in transfo nuc d cel ls II X9.
1901. These antigens seldom elicit an immun e response as most T ..:..:1Is with high or eve n
moderate avidity for scllpcptidcs arc el iminated durin g T ce ll selection in the thymus. In
animal model s and in vitro human systems, hctcroclit ic pcptidcs have been shown to
break Tc..:11tolerance and dramatically augment ce ll-mediated immunity against tumour-
associ.ucd antige ns II XX-190I. Slansky ct il l. 11921 attribute this enhanced antigen-
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specific antitumor immunity to increased stability or the pMIIC:TCR complex. which
results in increased avidity and residence time or this complex. However. the ability or
hctcroclitic pcpiid cs to hypcrstirnulatc T cells and generate high avidity interactions is not
sufficient on its own to eliminate tumors. The T cells that become primed by high avidity
hctcrocliiic pcptidcs must be able to undergo further activation and expansion driven by
the lower avidity. poorly immunogenic index pcptidcs, allowing the selective destruction
of transform ed cells that ovcrcxprcss the index sell-peptide 11901. Results l rorn current
clinical trials 1193.1 941 highlight the promise o r this approach. Based on these results \W
propose that the same principle may be applied to IIIV inf ect io n to selective ly augment
l llVvspcci fic CDXt T ccll responses.
In a study by Sette ct al. II XXI . potentially hctcroclitic variants were generated
from several IILI\ -1\2 and 1\3-rcstridc d rumor-associated pcpiidcs (9mcrs and lOmcrs)
and from two IILI\- 1\2-rcstrictcd viral pcptidcs, I\B V 1'01.455 and IIIV 1'01.476 (both
9mc rs). Peptide analogues that demonstrated hctcroclitic activi ty. regard less or index
peptide origin. each had amino acid substitutions that were o r conserva tive or
scmiconscrvativc nature at positions 3. 5. or 7 but never at positions I. 4. 6 or X. The
hcteroclitic pcptidcs identified, includin g two fill' the IIIV 1'01.476 index peptide.
produced up to a 107-fiJld increase in T cell sensit ivity to peptide stimulation and were
associated with higher magnitude responses II XXI. X-ray crystn llography-infcrrcd 3-
dimensional structure o r IILI\ -1\2 and 1\3 pMIIC:TCR complexes show that side chains
or amino acids at positions 3. 5 and 7 in the IILI\-1\2 and 1\3 binding pcptidcs interact
direc tly with the CDR3 regions oft he TCR u and 1\ chains 1195. 1961 thus suggcsting that
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hctcrocl icity is a result o r enhanced TCR recognition. The study by Selle ct u] . II XXI also
included a tab le or similarity scores fill' each amino ac id in relat ion to the others. These
relationships were qua ntified by ave raging the rank coe fficient score fill' to lerability or
point mutatio ns within a protein (Dayho ff PAM 250). hydrophobicity (an avera ge or
Kytc/Doo liu lc and l-auchcrc/I'l isku scales). and amino acid side chain volume (measured
by 1120 disp lacement) for each amino acid pair. We propose that hcicroclitic variants or
IIIV index pcptidcs can be generated in the same manner as in the study by Se ne ct al.
IIXXI and incorp orated into therapeutic IIlV vaccine design.
1.3... C ent ra l mcmorv T cells as a tar~et (If therapeutic IIIV vaccines
The sustained presence or IIIV-speeifie CDX' Tn! cells in LTNP is strongly
correlated with contro l or IIl V replication and slower disease progression 115X. 1591. The
Tn! lineage is characterized by the CD3 ' CDX'C IH 5RAT D2X'CC R7'C D I27'
phenotype 11971. Tl' ~ l produce IL-2. undergo se lf-renewa l. have a broad TC R repertoire
and serve as progenitors o r new eff ec tor and memory T ce lls 119XI. Most importantly.
Tl'~ 1 appear to be extre mely rare in progressive IIl V i n fectio n 1144. 1971. Renewal orT n !
appears to be de pendent on low-level antige n persistence and continued pro lil crut ion.
l lowc vcr, in cases or chronic in fection. when high viral loads persist. renew al is less
frequent leading to a decline in Tn ! populat ions 1151. 1971. The requirements for
commitment to the long-l ived Tl ' ~ l lineage is not fu l ly understood but is likely designated
early during T cells responses involving Al'C vpriming 119XI. Further insight into this
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process o r differentiatio n would allow us to design vacci nes that could selectively target
T(, ~I . l lctcrocliti c peptidcs enhance cell-med iated immune rcsponscs by exposing the
immune system to pcptidcs that arc rare or non-existent in cliuicul l ll v iso lates leadin g to
the activation or cos: T cells that arc cross-reac tive with the natu rally-occurring III V
pcptidc s. We propose that hctcroc litic pcptidcs, which selectively target IL-2-producing T
cells. may offer the approp riate level or ant igen stimulation to be selectively recognized
by or lead to the genera tion or e n g' Tc M. II' this holds true. then hctcrocl itic pcptidcs
should be incorporated in therapeut ic IIIV vaccine s as their ab ility to enhance recogni tion
by. or generation o r Tn ! could result in improved con trol or IIIV replication and slower
disease progressio n.
l..t Preliminarywork
Preliminary work 1'01'this project was com pleted by Juli a l'ohl ing, Nutusha Hollett
and Katrin Zippcrlcn, The first step in this proj ect was to identify IIIV peptide» that
stimulated 11.-2 production by e n g; T cells in l llV-infcctcd indiv iduals. PIHvlC from
l llV-in fcctcd subjects were screened 1'01' IFN-y and 11.-2 product ion by ELiSPOT assay
with overla pping lSmcr peptide sets spanning the major IIIV clade B antigens (Nationa l
Institutes or l lcalth AIDS Reference Reagent Program). Individual pcpt idcs were pooled
in sets 01'49 (Ncl) . 123 (Gag). 125 (1'011). 123 (1'012). 12g (Env l ), and 1U (l.nv.").
Initially. more than 40 indiv iduals were screened against the poo ls by ELiS POT assay to
determine which pools elicited 11.-2 responses. Twelve individuals from this initial
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screening had >200 IL-2 spot form ing units (SF lJ)/ 10(' I'BMC against one or more o r the
IIIV peptide pools. with IIIV Gag and Netpools eliciting IL-2 responses most frequently,
Those individuals co ntributed I'lHvlC lo r fo l low -up studies to ident i fy individ ual IIIV
pep iid cs that stimulated this response. I'ools stimulating IL-2 production (Gag and NcI)
were then dcconvolutcd with peptid e matrices by IJ-I SI'OT assay to identi fy individual
l Smcrs responsible. The Gag matrix (Figure IA.I 1\) consisted o r 20 poo ls or II
pc ptidcs . 2 pools o r 12 pc pti dc s and I pool or 2 pcp tidcs (1 23 pcpiidcs total ) in an II x
12 grid and the Nc f matrix (Figure IA.I B) consisted o r 14 pools or 7 pc pt idcs (49
pcptidcs total) in a 7 x 7 grid. Each peptide was present in two and only two pools. By
comparing the pattern or IL-2 product ion against the peptid e pools. the spec ific pept ide or
pcpt idcs responsible for IL-2 product ion were idcnti lied. Seve ral or the lSmcr peptide»
identified contained optimally defined CDX' T cell cpitopcs consistent with the II LI\
class I type o r the participant tested . 1\2-7 (Ncf X3-7( 1). 1\2-X (Ncf 135-7143). and 1\2-
Gag (Gag 77-7 X5) (all IILI\ -1\2 restricted) and 1\3-2 (G ag l X-7 27) (1ILI\ -1\3 restricted )
were confir med by ELlSI'OT assay as optimally defined ()mer pcptidcs stimulating IL-2
producti on by I'BM C from two or more l llVvinfcc tcd indiv iduals in our cohort. I'BMC
from an addi tional (,0 subjects who expressed the appropriate II LI\ class I molecule s
we re then screened by ELlSI'OT assay aga inst these index pc pt idc s fo r IFN-y and IL-2
production.
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8 ) Netpep tide {.XJols
Fi:,:ure IA.I The Ga:,:and Nef matrices. A) T he Ga g mat rix co ns ists or 23 poo ls (poo l
numbe r is high ligh ted in g ree n). Pool s I. 2 a nd 12-22 eac h co nta in I I pc piidc s who se
seq ue nce is iden tifi ed by a n ide ntific a tion number (ex 7'11.72 ). Pool s 3- 11 eac h conta in 10
pcptidcs and pool 23 co ntain s 2 pcptidcs ( 123 pc ptidcs tot al ). B) T he Ncrmatr ix co ns is ts
or 14 poo ls (poo l num ber is highl ighte d in ora nge) eac h co ntai ning 7 pcp iidcs w ho se
seq uenc e is ident ifi ed by a n ide ntifica tion number (ex 5 139 ). T he pool s were tested by
ELi S POT assay. Eac h pept ide was prese nt in two a nd o nly tw o pool s the ref or e by
co m pa ring the pattern or IL-2 produ ction ag a inst the pep tide pool s the spec ific pepti de or
pcp tid cs respo nsib le fill' IL-2 produ cti on were ide nti fied .
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From 1\2-7. 1\2-X and 1\3-2. eighteen potentially hctcroclitic variants were
de signed by making con se rva tive and scm ico nsc rvativc substitutions at positions 3. 5 and
7 as in the study by Sette 11XX I. The choice o r amino acid to be substitutcd was bascd on
the relationship to the index amino acid and rarity or absence among IIIV-I clade n
seq ue nces subm itted the Los A lamo s IIIV seq uence data base
(www.hiv.lanl.gov/contcnt/scqucncc/IIIV/mainpallc.html). Choosing variant pept ide
seq ue nces that arc rare or a bsen t innatural l llV- I infection is important. In chronic IIIV
infection. the infected individual' s immu ne syste m. has been ex pose d to a variet y ofl llV
c pitopc s but has not been ab le to c lea r or. in many case s, control the infection. Th e T
ce lls that reac t typically recognize the immunod ominant IIIV cp ito pcs, the ref o re T ce lls
recognizing non-immunodominant cpitopcs do not expand, l lowcvcr, T cells recognizing
immunodo rn inant cpitopcs eventually become functionally exhausted therefore, in order
to stimulate new T cell subsets or reactivate exhausted T cells, we must expo se them to
new cpiiopcs. More than 10 individuals were screened against the potent ially hctcroclitic
variants by ELiSPOT assay and at least 6 responded to one or more ofthe variants with 2:
50 IL-2 SFlJllOh PBMC. This preliminary data formed the basis or the current study in
which add itional variant sets were generated and PBMC from additional subject» were
screened against the original and the new variant sets, The spec ific aims or the current
study arc de scribed below .
4 1
1.5 S pec ific a ims
1.5.1 Iden tify pcptides that se lec tive ly aug me nt IL-2 p rudu ction lIy III V-speci fie
C Ult T ce lls relat ive to index pcp tidcs
The fir st aim of this study was to identify potentially hctcroclitic pcptidcs that
selectively augment IL-2 production by l llV-spccific ens' 'I' cells relative to index
pcptidcs. IL-2 production was measured by ELiSPOT assay. a simple and rapid test that
allows the cnumcrution of cytokinc-producing cells. At the beginning of this study. we
speculated that the ability of l llV-spccific CDX' 'I' cells to produce IL-2 correlated with
delayed disease progression and viral control. This correlate of protection was inferred
based on the association of LTNP with the sustained presence ofl llV-spccific CDX' Tn!
cells. which have the ability to produce their 0\\11 IL-2 and sustain their own proliferat ion
115X. 1591. In a recently published study by Akinsiku ct al. 114 11 the capacity of II IY-
specific CDX' 'I' cells from progrcssors and controllers (neither on ART) to produce
effector molecules (CDI07a. IL-2. IFN-y. TNF-u. pcrforin) and inhibit Ill Y replication
in autologous CD4' 'I' cells was measured. Results from this study showed a strong
correla tion of suppress ive capacity of CDX' 'I' cells with polyfunctional. IL-2 production.
Although no single functional output of CDX' 'I' cells can be used as a correlate of
protect ion. this study validates our use of IL-2 product ion by l llV-spccific CDX' 'I' cells
as a marker of enhanced immunogcnicity and functiona lity o r hctcroclitic pcptidcs
relative to index pcptidcs.
Because IL-2 responses are rare in progressive IIIV infect ion, we also comp ared
the ability of reference and variant pcptidcs [0 stimulate IFN-y production by c n x' 'I'
cells. In a sett ing of high viremia. IFN-y secretion is the most resistant to functional
exhaustion than all other 'I' cell functions. In standard ELiSPOT assays measur ing IIIV-
specific immune responses. IFN-y is the most commonl y assessed cyiokinc 1199. 200 1. In
addition to this. previous researc h has shown that hctc rocliiic pcptid cs can increase
production of lFN-y and/o r intcrlcukin -l O(IL- IO) relative to ref eren ce pcptidcs I IXXI·
1.5.2 In vest igat e whether IL-2-indu ein ~ het eruclitic IIIV pcpt id cs au gm cn!
pru liferu tion and diffcrcnt iatiun of ens' T cells
The second aim of this study was to comp are the capac ity of IL-2-inducing
hctcrocl itic pcptid cs and index pcptidc s to drive prol iferation and diffcrcn ti.uion ofC n X'
'I' ce lls, The ability o f Tc M to produce IL-2 allows them to support their own prolifcration
115Xl therefore we will test the ability o f potenti ally hctcrocliti c IIIV pcptid cs to induce
proliferat ion of these cell s in the absence o f any exogenous cytokincs. PBMC were
labell ed with CFSE. stimulated with either potenti ally hctcrocl itic or index pcpt idcs in the
absence o f exoge nous cytokincs. and cultured for 7 days before sta ining for flo w
cytomc try. Four colo r flow cytomct ry was also used to determ ine whethe r the IL-2
inducing pcptidcs also drive di ff erenti ation of l ll v- spcc ific c n x' 'I' cells in the absence
or presence o f exogenous cytokincs.
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1.5.3 Measure T CIVpcptidc avidity of IL-2 inducing heteroclitic IIIV pcptidcs
rela tive to index peptides
T cell avidity is defi ned as the ability of T cells to respond to the lowest
concentration of peptide in the context of the appropriate scll-Ml lt' molecule. Il igh
avidit y CDX' T cells require lower amounts of peptide for triggering of e ffector functions
while low avidi ty CDX+T cell require higher amounts of pept ide. Several studies identify
T cell avidity as an important parameter for cell-mediated control 1201-2031. Almeida <,1
al. 120 11 show that the presence of high avidity IIIV-speci lic CDX' T cells, which arc
polyfunct ional in nature, is strongly correlated with enhanced control of IIIV replication.
Using deple tion studies, l.ichtcrfcld ('/ al. 12031 showed that loss of high avidity IIIV-
speci fic CDX' T cells is strongly associated with disease progression in l llv -inlcctcd
individuals. Based on the importance of TC k/pcptidc-Hl.A class I avidity II))' IIIV
control. we also tested the ability of IL-2 inducing heteroclitic pcptidcs to enhance
TC k /pcptidc-Hl.A class I avidity relative to index pcptidcs,
I.SA T es t the ahility of IL -2 inducing hetcroclitic IIIV peptidcs to ~c n c ra t c
b roa d ly reactive CT L
l lctcroclitic pcptidcs enhance cell-media ted immune responses by priming CI)X'
T cells with naturally rare or non-existent peptide leading to the activation of CI)X' T
cells cross-reactive with the naturally-occurring pcptidcs, Because the IIIV RT lacks
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proofreading capacity. many viral quasispccics. including those with drug-resistance and
immune escape mutations. can exist within a single individual 1621. In order Ill! " a
hctcroclitic IllY peptide to be effective in a therapeut ic vaccine it must activate ClL that
arc broadly reactive agai nst mult iple variations o r the Ill Y peptide which may occur in
the host. Therefore, we also tested the ability or IL-2 inducing hctcroclitic Ill Y pcpiid cs
to generate ClL that arc not only cross-reactive with the index peptide but broadly
reactive with the entire variant set.
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C ha pter 2 M ate ria ls and M ethods
2.1 S tudy participants
l llVv inlcctcd study participants (numbered 1 to 257) were recruited through the
SI. Jolin' s Genera l Ilospital I llY Clinic, St. John' s. Newfound land, Canada. Non- infected
study participan ts (numbe red 1000 and above) were recruited through the Faculty of
Medicine , Memor ial University of Newfou ndland, St. John' s. Canada. 1\11 partici pants
provided informed consen t fill' whole blood collection and immunological studies. I'lHvlC
from over 40 l llVv infcc tcd part icipants were initially screened against the major Ill Y
antigens for 11.-2 production to ultimately identify 9 mer pcptidcs responsible for this
response. Those l llV- in fcctcd partici pants who originally responded and an addi tional 52
individuals who expressed the appropriate 111.1\ molecule (111.1\-1\2, 1\ ] , B1X, IU S, or
B57) were selected for hctcrocliiic pept ide testing against Ill Y and non- l llV peptide sets.
Most l llV-in fcc tcd study participants were on untirctrovira l therapy and had achieved
viral suppress ion to below limits of detection with clinical tests at the time of
participation . Non-infected study participants expressing the appropriate 111.1\(111.1\-1\2)
were selected for hctcroclitic peptide testing agai nst non-IllY peptide sets and used as
negative controls against interesting hctcroclitic Ill Y pcptidcs elic iting 11.-2 responses in
IIIY-ink cted study participants. lithical approva l for this study was granted by the
Memorial University of Newfoundland Faculty of Medicine l luman Invest igation
Committee.
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2.2 PBl\IC isolatiun
Whole blood was collected by fore arm venipu ncture into acid-citrate-dextrose
(t\C D)-co ntaining vacutaincrs to prevent coagulation dur ing visits scheduled for cl inical
tests, Alter centrif ugatio n at 400 g for 10 minutes. most of the plasma \\"iI S remove d.
aliquoucd and store d at -XO"c. The remaining blood was diluted 1:4 in phosphate
buffered saline (PBS) and PlHvlC were iso lated by Ficoll-l lypaquc (Cil: l lculthcarc Bio-
Science s) density gradient centrifugation . In short. a solution of Ficoll and sodium
mciri zoa te o f specific density was layered below the PBS-dil uted blood and ccntri tugcd
at 400 g fix 30 minu tes, This caused sedimentation of the eryt hrocyte s and granulocytes
to the bottom of the tube allowing co llection of PIHvlC from the plusmu-Ficoll interlace .
PBMC were used fresh or cryo prcscrvcd in lymph ocyte medium (Rl'M l 1640
supplemented with 10'% fetal calf serum (FCS). \00 pg/ml streptomyc in. 100 IlJ/ml
pcnicillin .2 mi\1 L-glutam inc. 10 mM IIEPI:S buffer and 2 x Io' M 2-mcrca ptocthanol:
a ll Invitrogen ) with FCS increased to 20'% and supplemented with 10'%
dimethyl su lfoxide (DMSO ) (S igma).
2.3 Epstein-Ba IT viru s (EBV) trun sformntiou Ill' B cells
EBV transform ation of B cells is an effective procedure fix immorta lizatio n of
human B lymphocytes 12041. The IN 5-X cell line (I:BV transformed marmoset
leukocyte s) is a marm oset ce ll line that releases high titrcs of transfonu ing I:BV and can
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thus be used as a source of EBV to estab lish continuous B cell lines from human dono rs.
IN S-X cel ls, establi shed in cu lture, were ccntri lugcd at 1100 rpm for 5 minutes. The
supernatant was poured off into a sterile 15 ml tube and fil tered through a OA5 !II'"I
acrodisc syringe filter (PALL Corporation) to ensure com plete removal of cell s. 2.5 ml of
filtered supernatant was added to 5 x 1({, fresh ly isolated PBi'vIC and incubated lor 24
hours at J r C in 5'1. CO2. Aller 24 hours. the ce lls were centrifuged and resuspended in J
ml of lymphocyte medium with rcs increased to 25% and supplemented with I pg/ml
cyclosporin A (Nova rti s). The ce lls were incubated at JrC in 5'1.. C0 2 for two weeks
before adding more lymph ocyte med ium. When a sufficient number o ftra nsformed ce lls
was grown (6-Xweeks). as indicated by the appearance of large cellular masses that cou ld
be seen by the naked eye. a stock of lO x 101> cells/via l were cryop rcscrvcd in liquid
nitrogen. B cell lines were estab lished forull parti cipants in this study.
2.4 li LA tYJli ll~
All samples received prior to Sep tember 20 I0 were II LA typed for Class I A and
B antigens with the Lambda Monoclo nal Ty ping Tray Seco nd l Il.A Class I. Lot 6A (One
Lam bda). This kit is a serolog ical typing method in which monoclonal antibodie s (0 most
l ll.A specific ities and complement. prcdou cd onto the microtcst tray. arc mixed with an
equal volume ( I ul) of ce lls at 2-4 x 10(' cclls/m l. The react ions arc read following a I
hour incubation period. Aller September 2010. the Micro Sequence Specific Primer
(SSP) l ll .A Class I D A Typing Tray (One Lambda) was used for l ll .A typing. This
DNA-based tissue typi ng technique uses com pletely matched oligonucleotide primers to
amplif y a target sequence corre sponding to a particu lar l ll .A allele . The primers and
internal controls are prc-aliqu otcd into a 96-well format and requir e on ly the addition or
25-200 ng/pl DNA ( 100 ng/ltl is optimal) and reco mbinant Taq polymera se (5 !JIp l).
PCR was performed using the PTC-IOOI~l Programmable Therma l Controller (M.I
research, lnc.) as per kit instructions. Alter PCR, the DNA fragments were separated by
gel electro phoresis. stained with cthid ium brom ide and exposed to lJV light tor
visualization. The presence or absence or specific bands indicated the presence or
absence ofspecific alleles.
2.5 ELiS POT assays
I'BM C samples from more than 70 l ll Vvin fccrcd participant s were stimulated
with poo ls or overlappi ng lSmcr pept ide sets spanning the major IIIV clade B antigens
(Nationa l Institutes o r l lcalth AIDS reference reage nt program). Individual peptide » were
disso lved in DMSO.then pooled in sets 01'49 (Nel). 123 (Gag), 125 (1'011),1 23 (1'012).
12X (I:nv l). and X3 (I:nv2) in unsupplcmcnicd RI'M I 1640 at a final co ncent ration or 1.0
ug/m l or each peptide. PBMC were used fresh or thawed and cultured overni ght at
37"C/5'X. CO~ in lymphocyte medium before cou nting viable cells using the trypan blue
exc lusion method . Multixcrccn 96-we ll plates (Mi lliporc) were pre-wetted with 50 pi or
35% ethanol. washed 4 times with PBS and coa ted overnig ht with 100 p i/we ll or 7.5
pg/mI IFN-y mAb I-D IK or 15 Ilg/mIIL-2 mAb IL2-1/249 (both Mabicch) at4 "C. The
plate was washed 4 times in PBS then 2 x 10' or 4 x 10' cells at a concentration or 2 x
106 cells/nil in lymphocyte medium were added per well for IFN-y and 11.-2 detection ,
respectivel y. in single (11.-2) or dual (IFN-y) replicate s. Pcpiidcs (10 pi/pool rill' IFN-y
and 20 ul/pool rill' IL-2) were added at a fi nal concentr ation or 0.1 pg/ml. Medium alone
was used as a negative control and 5 pg/mL phytohema gglutinin was used as the posit ive
control. After overni ght incubation. the plates were washed 6 times with PBS then 100
ul/wcll or I ug/ml 7-B6-1-biotin or IL-2- II-biotin (both Mabtcch) were added for IFN-y
and 11.-2 detecti on. respectively . for 2 hours. Plates were washed 5 times with PBS and
100 ul/wcl! or a 1/1000 dilution ofstrcptav idin-alkalinc phosphatase (ALP) (Mabtcch)
was added for I hour. Plates were subsequently washed 5 limes with PBS and 100 ul/wcll
or chromogenic ALP substrate (Biokud) was added. Strcpia vidin has a high affi nity IlH'
biotin therefore any biotinylaicd antibodies used to detect either IFN-y or 11.-2 arc bound
by enzyme-conjugated strcptavidin. ALP then convert s the chromo genic substrate. a mix
or nitrobluc rctrazolium in aqueous dirncthylformamidc (DMF) containing magnesium
chloride and 5-bromo-4-ehloro-3-indolyl phosphate in DMF. into an iododyc which is
bound in place on the membrane forming a purple spot. I:ach spot is equi valent to one
reactive cell. Spots were counted with an lmmuno scan reader (Cclluar Technology
Limited) . Qualit y control was performed manual ly and results were reported as IFN-y
SFlJ / IO(' PBMC or 11.-2 SFlJ/106 PBMC. A positive response was considered to be at
least SO IL-2 SFlJ/106 PBMC or 100 IFN-y SFU/106 PlHvlC and at least twice the
background.
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Pools stimulating IL-2 production (Gag and NcI) were dcconvolutcd with peptide
matrices by 1:L1SPOT assay (as above) to identify the indiv idual lSmcrs responsible . The
Gag matrix consisted o r 20 pools or II pcptidcs, 2 pools o r 12 pcptidcs and I pool or 2
pcptidcs (123 pcptides total) in an II x 12 grid and the Ncr matrix consisted or 14 pools
o r 7 pcptidcs (49 pcpt idcs total ) in a 7 x 7 grid. Each peptide was present in two and only
two pools. By comparing the pattern or IL-2 production against the peptide pools the
specific peptide responsib le 1'01' IL-2 product ion was ident ified , Several or the lSmcr
pcptidcs identified contained optimally defin ed cos' 'I' cell cpitopcs consistent with the
IILI\ class I type or the participant tested. 1\2-7 (Nc r li3-.791). 1\2-li (Ncr 135-.7143). and
1\2-Gag (Gag 77-.7li5) (all IILI\-1\2 restricted ) and 1\3-2 (Gag l li-.727) (IILI\-1\3
restricted ) were con fi rmed as optimally defined 9mer pcptidcs stimulating IL-2
production by PBMC from two or more l llV-infccicd individuals in our cohort. From
these pcptidcs, twenty-four potentiall y hctcroclitic variants were generated (described
below) and tested by 1:L1SPOT assay as above except that 10 pi (IFN-y) or 20 pi (lL-2)
or 40 ~ lg/m l peptide was added to each well 1'01'a final pept ide concentration 01'.:1 ~ lg/m l.
Additive ELiSPOT assays were used to determin e i f ove rlapping or di ffe rent
subsets 01''1'cells respond to both reference and hctcroclitic pcptidcs, Addi tive ELiSPOT
assays were performed as above 1\)1' IFN-y detection in terms or plate coaling and
detection , 200.000 PBMC were added per well and stimulated with 4 pg/ml or reference
peptide. 4 ug/ml o r variant peptide or a combination or reference and one variant pept ide
at .:lpg/ml each peptide.
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2.CI Hctcroclitic pcptides
Potenti ally hctcroclitic pcpt idcs were generated by making con servative and semi-
conservative substitutions at amino acid positions 3. 5 and 7. Subst itutions were made
based on a table o r similarity scores 1'01' each amino ac id in relation to the others. These
relationshi ps were quantifi ed by averaging the rank coe ffic ient score for tolerabilit y or
poin t mutations within a protein (Dayhoff PAM 250). hydrophobicity (an average or
Kytc/Dooliul c and Fauchcrc/Pli ska scales). and amino acid side chain volume (measured
by 1120 displaceme nt) 1'01' each amino ac id pair II SSI. In addition to aa relationship s.
substitutions were made based on rarity or absence among III V-I clade II sequences in
the l.os Alamos IIIV sequence database
(http://www.hiv.lanl.oov/content/sequeneclOLJIC K ALIC.N/OuiekAlign.htmll. Positions
3. 5 and 7 were selected for substitutions based on X-ray crystallograph y-inferr ed 3D
structure o r II LA-A2 or A3/peptide/TC R co mplex that revealed side chains o r amino acid
at these positions arc most ex posed to the CDR3 regions o r the TCR u and 1\ chains 1195.
1961. Because the anchor residues 1'01' III.A-A2 and - A3-restrieted pcptid cs arc at
posit ions 2 and 9. substitutions at positions 3. 5 and 7 should not alter li LA-b inding.
Seve ral or the pcptid cs used were presented by III. A-A2. A3 and/o r additional l ll .A
molecules. Add itional IIIV variant pcptid cs were made using (Jag I47-) 155 (1157- 1:
III.A-1l57 restricted ) and (Jag433-) 440 (A2-9: III.A-A2 restr icted ) as reference pcptidcs.
III.A-1l57 also has anchor residues at positions 2 and 9: therefo re. B57-1 variants were
synthesized as abov e. Because A2-9 is an Smcr. substitutions were made at positions 3. 5
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and x. Substitu tions at position X may have disrup ted II LI\ -1\2-binding. II LI\ -1\2-
restri cted non-IIIV (1\2-Flu and 1\2-11') peptide variant sets were gene rated as above lor
I ILI\ -1\2-restricled pcptidc s. Potentia l hctcroclitic peptide sequences arc shown in Table
2.6.1.
Binding predictions were performed using the Center for Biological Sequence
Analysis (Tec hnica l University or Denmark) Nctlvl l lt,' 3.0 server. which predicts binding
or pcptidc s to a number or diff erent 111.1\ alleles using art ificia l neural netwo rks (I\N Ns)
and weight matrices rhu1://www .cbs.dlu.dk/services/NetM IIC-3.0/). Unfo rtunately, this
was perfo rme d a fter pept ide syn thesis. Many var iant pcpt idcs enhanced binding or had
similar binding to the appropriate II LI\ rela tive to the referen ce peptide. Few pcpt idcs
weakened binding or did not bind. The results arc shown in Ta ble 2.6.2.
2.7 CT L ass ays
CT Ls were generated by stimuluting 5 x lOt> I'IHvlC. centrifu ged and resuspend ed
in approximately 100 !t1or lymphocyte medium. with 100 !t1or pept ide at 200 !Ig/m l lor
a final pept ide conce ntra tion o r 100 !Ig/ml. Following I hou r or incubat ion at 37"C/5'X.
C0 2. cells were resus pended at 2.5 x lOt> I'BM C/ml in lymphocyte medium supplemented
with 25 ng/111 I ofreco mbinant human IL-7 (Na tional Cancer Institute (NC I) Repository).
On day 3. 20 U/ml exogenous IL-2 (NC I Repository) was added. CT L activity was
assessed between days Xand II by 51Cr release assay. using peptid e-pulsed autologous or
l ll.Avmatchcd I:BV-lransronn ed B Iymph oblastoid ce lls (BLCL) as targets. I x lOt>
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Ta hlc 2.6. 1 A co mpa rison of reference and cor res po ndi ng varia nt pept ide seq ue nces
Reference Peptide Variaut l'cpiidcs li LA Restriction
(nuruc . jx i sit io n. aa scqucucc) ( uurue r an scqucncc}
j ;\ ~t S : II 1\2;\2 -7(Nc IX3):;\ /W IJI.S I II·1. IV ISI Ii I 1\ \\ (,11~ ~ ~~12 Ih\ h2
~ ~. ,W 'F 1\2;\2-X( Nc rJ 35 ): YI' I.T F<,WCI II IX1135:1
j ,\ .\;\ 3- 2( ;ag IX): KIRI.RI'( ;(; K 1\71127;~ ~
;\ 2-( ;ag( <iag77 ):S I.YNTVA I I. ;~ ::~ : ;:: ;~~~ 1\2
~ g-- : ~ ~~ ci l
,ae-' III
1\57- 1 (<i ag l ~ 7 ) : I.SI'RII.N;\W : ~ >~II. ~ ;, 1157
II. I;\\'
;\ 2-' )«;ag·l.\3) : I,'U ;K IW I'S ~ '~~~;:,' 1\.2
's'
;\ 2-F III:(; II.(; FV FT I. ~ :::I jJ::: 1\2II-!>: v iiu
,\ · 1 I.I.NVI' I ;\ ;\ V
;~ I.l. l VI'I' ;\ ;\ V;\2 -11': I. I.IJ VI' I ;\ ,\ V 1'-3 I. I.IJ VI 1';\ ;\ V
;~ I' -~ 1.1.l lV NT;\ ;\ V 1\21'-5 : I. I.IJ VPI~;\ V
1'-(,: I. I.IJVI' I 1';\ V
Differen ces lrom thc reference peptide arc highlighted III red and underlin ed
* marks pcptidcs that el icited 11--2 production by e m; ' T cells
54
Table 2.6 .2 : liLA-Bind ing Predictions for Reference and \ ariant Pcptides
51!
51!
51l
51!
51l
51l
51l
51!
51!
WI!
51!
51!
51!
WB
W B
51!
W I!
W I!
WI!
WI!
WI!
WI!
WB
5B
5B
51!
51l
51!
5B
51l
Wil
WB
WB
WI!
W I!
W I!
IILA-A2
WI!
Wil
W B
Hind Lev el For given III.A
Wil
Wil
Wil
W I!
Wil
51l
WI!
2BI24
21l7B4
26403
27026
29372
2 1710
23095
17
43
69
11
36
30
53
162
132
123
52
15
589
73
19
4 1
27
18
48
35
199
83
80
152
1584
193
204
137
544
140
999
259
363
1394
6309
211484
3(,189
3(,26 1
33274
3(,320
28306
28228
64
103
131!
110
13 1
48
53
IIIA-A2 [1l60, 1l62 not available)
39 166
4 1001
43500
37008
35%3
38696
47774
IILA-A2
f--- - - ..,..,.34.,-1 ----+--- --==--- - -j
126
188
949
204
3
2984
55
48 51!
'1'1 \VI!
146 \VB
2'1 51!
V ~
B'J \VB
A2-1I'-b: LLlJVIYr rAV '18 5B
Differences I~-om the reference peptide are highlighted in red and underlined
* marks pcptidcs that elicited 11.-2 production by CDX' T cells
Strong binder is denoted by SB_SB threshold is 50 ni\l
Weak binder is denoted bv WB_WB threshold is 500 ni\1
Non binders are indieateJ by a blank. Non binder threshold is >500 nM
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BLC L were incubated with 100 pCi or sodium chromate ( a/' CrO~ ) . which was
absorbed by passive transfer. Following a 90 minu te incubatio n. cells were washed once
in PBS. twice in PBS supplemented with )'% FCS and once in lymphocyte media, Viab le
cell s were cou nted using the trypan blue exc lusion method then resuspended at I x Ill '
ce lls/nil. 50 ~t! BLCL were added to a 96-well U-bottom microtest plate (Becto n
Dickinson ) then pulsed with 50 !t! or 40 ug/ml peptide or unsuppl cmcntcd RPI'vIl 1640 as
a negative co ntrol. in duplicate. lor one hour. 50 pi BLCL added to 250 pi I N hydro gen
chlor ide (lI CL ) or 250 pi lymphoc yte medium . in duplicat e. was used to measure
maximum 51Cr release and spontaneous 51Cr release. respectively , CT L were washed
with lymph ocyte media to remove excess 11.-2 and co unted using the trypan blue
excl usion method. CT L were resuspended at 5 x 10' cell s/nil and added at 20: I. 10: I. 5: I
and 2.5: I cff cctor.i urgct rat ios. in dup licate, Lymph ocyte media was added for a Iinul
volume or 300 ul/wcll prior to a 5 hour incubation at 37"C/5"/" CO2, Pept ide-specific CTL
recognized Bl.Cl .vprcscntcd pcptidcs and exe rted effector functions. kill ing the BLCL.
thus causing release Or51Cr into the supernatant. 125 pi o r supernatant was added to 50 pi
or bleach in co unting tubes (Fishcrbrand) then placed in a 141W WIZARD '\! Automatic
Gamma Counter (Pcrk inlilmcr) which read the amount or radioacti vity present in each
tube, The percent specific lysis was calcul ated from the amount or 51Cr present in the
supernatant or the test wells relative to the amount or "Cr present in the supernatant or
the maximum and minimum release wells by the Iollowin g Iormula:
'X.specific lysis = test " Cr release - min "Cr release
max 5lCr release - min " Cr release
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Cross-reactiv ity assays were performed by ~ I C r release assay in which autologous
BLCL were pulsed with each peptide in the entire peptide set. Effector cells were added
at an appropriate effec tor.target ratio determined in the previous assay. Results were
plotted as percent spec ific lysis against each peptide. Avidity or the TC R/peptide
interaction was also determined by ~ I C r release assay in which autologo us BLCL were
pulsed with serial dilution s {I0 ~11'v1 to I x Io' ~ll'v1 fina l) or the test peptide . Effector cells
were added at an appropriate effector.ta rget ratio based on the previous assay. The results
were plotted as percent specific lysis against peptide concentration and the avidit y was
estimated as the concen tration or peptide at which the percent specific lysis tell to 50'X,o r
the maximum.
2.H Prulifcratiun assa ys and flow cytomet ry
Proliferation assays were performed using the Cclllracc" CFSE Cell
Proliferation Staining kit (Invitrogen). 1\ 5 m -( stock solution o r CFSE was prepared by
dissolv ing 50 Ilg CFSI: in IX III I)MSO . PBMC were resuspended at I x 101> cel ls/ni l in
pre-warmed PBS supplemented with 5 mM 1:1)'1'1\ (Sigma) and 0.25 ~IM CFSI:
(Invitrogen) and incubated . in the dark. at 37"C fill ' 14 minutes. Following a 5 minute
incubation on icc the cells were quenched with 5 volumes o r icc-cold lymphoc yte media
and centrifuged to remove any unabsorbed CFSE. 2 x 101> to 5 x 101> PIHvlC (depending
on availab ility) were cen trifuged and resuspende d in approxi mately 100 III or lymphocyte
medium. with 100 III or peptide at 200 Ilg/ml for a final peptide concentr ation o r 100
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Ilg/ml. Following 1 hour or incubation at 37"C/5'% CO2• cells were resuspended at 2.5 x
Ht PBI'vIC/ml in lymphocyte medium , On day 7. cel ls were harvested and stained with a
four color panel for Sur l~ICC and intracellular markers using anti-CDX-PcrC P (l IITXa:
Hiol.cgend) and an appropriate color combi nation or anti-CC R7-APC (3DI2:
clsioscicnccs). anti-IFN-y-APC (4S.B3: cBioscicnccs). anti-PD-I -APC (E1112.2117:
Biol .cgcnd). unti-pc rforin-A l' Czl' E (dCi9: BioLcgcnd/ll -D4X: Santa Cruz). anti-IL-2-PI:
(rvlQ 1-17111 2: clsioscicnccs) and anti-CD45RA-PE (.lS-X3: cltioscicnccs). No FITC-
conjugated antibodics were used because CFS I: occupies the FITC channel. Addit ional
flow cytomctry experiments in which cells were not CFSE labelled involved appropriate
color combinations o r the previously described antibodies along with anti-IL-2-FITC
(I'vI Q I- 171112: Caltag). anti-IFN-y-FITC (4S.B3. c lI ioscic ncc s) and anti-CD3-FITC
(UCIIT I: clsioscicnccs), Staining lor intracellular cytokines (IFN-y and 11.-2) was done
alter a 4 hour incubation or 1 x 101> peptide stimulatcd-PBI\IC with I00.000 referenc e or
hctcroclitic peptide-pulsed autologous BLCL in the presence or 10 Ilg/m l (final
concentration) Brcfeldin A. Appropriate iso iypc controls were used, Staining was
performed as per IntraStain Kit (Dako) procedure, In short. I x 101> cel ls were washed in
llow bu ff er (PBS supplemented with 5 mM EDT1\. 0.2'% sodium azide (both Sigma) and
0.5%. FCS (Invitrogen) with the pi I adjus ted to 7-7.2). stained with antibod ies to surface
marke rs. washed, incubated with fixative containing 5-10%. formaldehyde. washed,
pcrmcabi lizcd and stained with antibodies to intracellular marke rs, After a linal wash.
cel ls were resuspended in 200 111 01'I'X, paraformadchydc and analyzed within one week
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or staining with a FACSCalibur '" (BD Bioscicnccs). Data analysis was performed using
WINMDI 2.S software,
2.9 Statistica l Analysis
Statistical analysis was carried out with Graphl'ad Prism 4.03 Software.
Normality or data distribut ion was assessed by IYAgostino and Pearson omnibus
normality test. When data was normally distribut ed, means were presented Il H'
compari son. Irdala did not lit a normal distr ibution. mcdians were presented IlH'
comparison. One-Ta iled Studcnts Paircd r test was used to compare 1'1)-1 expression on
reference and hctcroclitic peptide-stimulated CFSI:1" " CDS' T cells, Probability values <
(l.05 were co nsidered significant.
C ha pte r 3 Res u lts
3.1 A co m pariso n of IFN-y a nd/or I L-2 in du ct ion lIy re fe ren ce a nd poten tia lly
hetcr oclitic pep t ides
The first aim of this study was to identify pcptidcs that select ively augmented 11.-
2 production by l llV-spccific CDS' 'I' cel ls relative to refe rence pcptid cs, Because the
production or 11.-2 is rare in progressive II IV i n fectio n, we also tested the ability or
potentially hctcroclitic II IV pcptidcs to enhance IFN-y production by l IlVvspccific CDS'
'I' cells relative to refere nce pcpt idcs, Cytokinc production was measured by 1:L1SI'OT
assay in which I'BMC from S7 l llV- infcc tcd and 5 l llV -uni nfcctcd individuals were
screened in single (11.-2) or dupl icate test (IFN-y) against one or more oft he S pept ide
sets used in this study Crable 2.6.1) at one or more time points. Each or the pcptidcs is
9aa in length. with the exce ption or 1\2-9 and variants 1\2-9- 1 through 1\2-9 -5. which arc
Smcrs. The number or people tested against each pept ide set and the number or people
who had a positive response (at least twice background and 2: 100 IFN-y SFU/ IO(' I'BMC
or 2: 50 11.-2 SFU/l 06 I'BMC) to one or more pcpiidcs arc indicated in Table :1.1.1. In
most cases (1\2-7. 1\2-S. 1\2-9 . 1\:1-2. B57-1. 1\2-Flu. and 1\2-11'). less than 50'% oft he
subjects tested responded by IFN-y product ion and fewe r than 15'% or those tested
responded by 11.-2 production. For one peptide set, 1\2-Gag. 60%, o r those tested
responded by IFN- yproduction. while 2 1'X, responded by 11.-2 production .
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The se result s arc fairl y descriptive so in order 10 better under stand them . there arc
a few things 10 keep in mind . Firstly . a positive respon se is a t least twice back ground and
2: 100 SF U/l06 I'BM C I(Jr IF - YOI' 2: 50 SF lJ/I06 I'BM C I(Jr 11.-2. In co mparing IFN-y
respo nses . two pcptid cs were co nsidered similar if there was < 100 IF -y S FlJ/l 06
I'B MC difference, t\ peptide was con sidered bett er than another if ther e wa s 2: 100 IF -y
SFlJ /l06 I'BM C with a difference of 100- 300 IFN-y S FU/l 06 I'BM C repre senting a
slightly betic I' peptide. a difference of 30 1-700 IFN-y SF lJ/ I0 6 I'BM C repre senting a
moder atel y better peptide and a difference of > 700 IFN-y SF lJ/ I06I'BM C repre sen ting a
much better peptide. These ranges were chosen arbitrari ly based on the variation in
respon ses ob served . For 11.-2 respon ses. two pcptidcs were con sidered sim ilar if there
was :S 25 11.-2 SF U/I06 I'BM C difference, t\ peptide was con sidered better than another
if there was > 25 more SF lJIII06 I'B MC. The result s arc described in co mparing the
number of cases ( reference and hctcroclitic peptid e pair co mparisons) for each ca tego ry.
The to tal number o f cases is based on the number people and the ir respe ct ive pept ide-pa ir
comparisons that el ic ited positi ve respon ses.
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Tahlc 3.1. 1 1\ s u m m a ry of t hc n u m be r of peop le wit h po sitive IF N-y and 11,-2
rcspon scs to onc or mnre pcp tides in cac h peptide sct.
Pc rtide Set 1\2 -7 1\2 -S 1\2-9 1\2-{;a" 1\3-2 BS7-1 1\2-Flu 1\2- 11'
N u m hc r o f Pco p lc 2 1 26 15 37 19 7 10+ 7+
Tcstcd 5- .' -
( 1511total)
Numbcr ufl'cople 7 II 5 2 1 5
.' 4+ 1+
with Positive .'- 0-
IF N-y Responses
(611total)
Nu m hc r o f Pco p lc
.' 2 2 5 2 0 0+ Of-
with Po sit ive 11,-2 1- 0-
Responses
( IS tota l)
• + refers to l ll V vin fcc tcd individuals
• - refers to l ll v-un infccicd individuals
• Pep tide set re fers to bo th re ference and var iant pcpt ides
• 1\ posi tive respo nse is o ne that is a t leas t twi ce the back ground a nd at lea st 2:. 100
IFN-y SFUIIO(' I'BMC o r 2:.50 IL-2 SFU/ IO()I'BMC
• So me indi vidu al s were tested aga inst one o r mor e pept ide sets. therefore, the re is
overlap in the tot al numberofpeople tested a nd w ith pos iti ve respon se s
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In - 50'}). or those individual s who responded to one or more pcptidc s by IF -y
production. the reference peptide stimulated ~ 100 IFN-y SFU/IOh I'lHvlC more than all
other variants within their respective peptide set (Repre sentative exampl es shown in
Figure 3.1.1). In the majorit y or cases (19/29) the reference was only slightly better than
the variant s (100-300 IFN-y SFU/lOh I'BMC difference : Figure 3.1.1 1\). In 5 cases. the
reference was moderately better than the varian ts (30 1-700 IFN-y SF lJ/lOh I'IHvlC
difference: Figure 3.1.1 B) and in an additiona l 5 cases . the reference was much better
than the var iants (> 700 IFN-y SFlJ / IOh I'B MC differen ce; Figure 3.1.1 C). Thirty-seve n
percent o r those individuals who responded by IFN-y prod uct ion (22/(JO)had simi lar IFN-
y respon ses « 100 IFN-y SFU/ IOh I'BMC dif f erence) to the reference pept ide and at least
I. but up to 5. varia nt pcptidcs within a set (Represe ntative exam ples shown in Figure
3.1.2). For 1\2-7. a common trend was observed in which the reference peptide and
variants 1\2-7- 1 to 1\2-7-4 stimulated similar IFN-y respon ses in 3 or the 7 who
responded to this peptide set (#34. # 125 and # 13X: Figure 3. 1.3 1\). 1\ common trend was
also observed fix peptide set 1\2-X (Repre sentative example s shown in Figure 3.1.3 B).
Three or the eleven individual s who responded to 1\2-X. responded only to the reference
peptide . or the X remai ning individ uals who responded to at least one or the variant
pcptidc s. 1\2-X-6 rarely stimula ted a respon se. In cases where a respon se was generated. it
was less than 20% or the next highest respo nse to any ofthe pcpt idcs within that set .
B) #50
HLA ~,A3, !ru!,Bw67
#87
HLA A 2 . ~, B8 , B62
#166
HLAA2,A11 ,B49 lli
C) #229
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#11
HLA ~.A32,B18,Bw60
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Fi~ure 3.1.1 Compur isun of reference and variant stimulation of IFN-y p rurluction I.
I'B MC from l llV- infcctcd and/or l llv -uninf cctcd individuals were tested in duplicate
against one or more pept ide sets for IFN-y production by ELlS I'OT assay. Duplicates
were within 20'% o f eac h other. Dupl icates were ave raged and the background was
subtracted. A positi ve response is at least 100 IFN-y SFU/l 06 I'BM C and at least twice
background. Representat ive exa mples in which ref eren ce pcptidcs stimulated A) 100-300
B) 301-700 or C) > 700 IFN-y SFU/ \06 I'BMC more than all variants are shown. The
l Il.A class I allele that presents eac h pept ide set is highlighted in red and underlined.
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HLA ~. A 1 1 . ~. B44
#216
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#43
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HLA ~.A31 .B27.B44
#78
HLA A 1 . ~. !W!. Bw41
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HLA ~.A24.B14.B44
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Figur e 3.1.2 Compur ison of reference and vari ant stimula tion (If IF N-y pr oduction
II. I'BMC from l llV vin fcc tcd and/or l ll v- uninfcc tcd individuals were tested in duplica te
against one or more peptide sets lor IFN-y production by ELlSI'OT assay_ Duplicates
were within 20'% or each other. Duplicates were avera ged and the background wus
subtracted. A positive response is at least 100 IF -y SFU/lOh I'BMC and at least twice
background. Representat ive examples in which re ference and one or more varian t
pcptidcs stimulated responses within 100 IFN-y SFU/l Oh I'lHvlC ofeach other are shown.
Variant pcptidcs thal li t this criterion are indicated by arrows. The l ll.A class I allele that
presents each peptide set is highlighted in red and underl ined.
6X
A) #34
HLA ~,A3,B35 , Bw60
#125
HLA ~, A9 , B1 4 , B44
#138
HLAA3 ,A28 , Bw62
B) HLAA1 , ~~ ,BW41 #82HLA A3 , A24 , B7 , ~ #230HLA ~,A28 , ~,B44
69
Figu re J. I.J C om pa r ison Il l' reference and variant st im u lutinn Ill' IF N-y production
III. I'lHvlC tro rn l llVvinfcctcd individua ls were tested in duplicate against A2-7 and/or
A2-8 peptide sets for IFN-y production by ELlSI'OT assay. Duplicates were within 20'%
of each other , Duplicates were averaged and the background was subtracted . A posit ive
response is at least 100 IF -y SFlJ/l OI> I'BMC and at least twice background. A)
Representati ve examples of the trend observed for peptide sci A2-7 in which similar
responses to the refe rence peptide « 100 IFN-y SFU/l O(' I'BMC d iff erence) were
observed fix variants A2-7- \. -2. -3 and -4 while variants A2-7-5 and -6 stimulated weak
or no responses. B) Representative examples of the trend observed ttl! ' peptide set A2-8 in
which variant A2-8-6 rarely stimulated a response. In cases where a response was
generated it was < 20'% of the next highest response. The l ll.A class I allele that presents
each peptide set is highl ighted in red and underlined.
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In 9/60 responding individuals. variant pcptidcs stimulated more IF -y
production than their respective reference pcptides by ::: 100 IFN-y SFU/lOh PBI\IC
(Figure 3.1.4). In 4 or the 9 individual s who responded in this way. 2 or the varian t
pcptidcs within a peptide set lit this criterion . Therefore. a total or 13 reference and
var iant peptide pairs in which variant pcptidcs stimu lated more IFN-y exist. In X/ 13 pairs.
the variant was slightly better than the reference (100-300 IFN-y SFU/l Oh I'BMC
di ffere nce: Figure 3.1A A) with 4 additional variants being moderately better than their
correspo nding reference pcptidcs (30 1-700 IFN-y SFIJ/ IOh PBMC difference: Figure
3.1A B) and 1 variant being much better than its reference peptide (> 700 IFN-y SFlJ / IOh
PBMC difference: Figure 3.1A C). These results show that variant pcptidcs induced
similar or higher IFN-y responses to those induced by reference pcptidcs in - 50'% or
respondin g individuals.
As shown by the MERCK STEP trial 11671. IFN-y responses alone arc not a
strong correlate o r protection in IIiV infection . 11.-2 responses. however. arc associated
with the presence or HlV-spccific C[)X' T("~ I cells 115X. 159 1and arc strongly correl ated
with enhanced suppress ive capacit y or c))x+T cells 11411. Therefore , we tested the
ability ofre ference and variant pcptides to induce 11.-2 productio n by C))X+T cells. 11.-2
responses were measured by ELiSPOT assay in single tests at the same time points as
IFN-y responses were measured. We used selective 11.-2 production by C[)X+T cells as a
marker or enhanced inununogcnicity and functionality o r hcteroclitic pcptidcs relative to
index pcptidcs, The number or 11.-2 producing cells can also be used to estimate the
number or l ilV-spcci fic C))X+Tn 1. since these cells produce their own 11.-2to sustain
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Figure 3. IA Compnr isun of reference and variant stimulutiun of IF N-y productiun
IV. I'BMC from l llVvinfcctcd and/or l llV-uninfcctcd individuals were tested in duplicate
agai nst one or more peptide sets lex IF -y production by ELlSI'OT assay. Duplic.ucs
were within 20% or each other. Duplicates were averaged and the background was
subtracted. A positive response is at least 100 IF -y SFlJ/l O" I'BMC and at least twice
background. Representative examples in which variant pcptidcs stimulated A) 100-300
B) 301-700 or C) 70 1t IFN-y SFlJ/ IO" I'BMC more than reference pcptidcs are shown.
The l ll.A class I allele that presents each peptide sci is highl ighted in red and underl ined.
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their own proliferation As expected. 11.-2 responses were much less freque nt than IF -y
responses Crable 3.1.1). 11.-2 responses were observed in 15 individuals. however. I o r
these individuals (# 13 1) was tested on two dif f erent occasion s and his 11.-2 response
shilled to lit into two categories. therefore, an additional reference-varian t com parison
was added fix a total or 16. Two additional individuals (#34 and # I00 I) responded by 11.-
2 production to 2-3 variants. one similarly to the reference and the othcrt s) superior to the
reference, there fore, two additional cases were added 1'0 1' a total or III cases. Reference
pcpt idcs stimulated more 11.-2 (> 25 more 11.-2 SFU/ IOf> I'lHvlC) than variant pcpt idcs in
3 or I II cases (Figure 3.1.5). A third or those individ uals who responded by produci ng 11.-
2 (6/ 111) had similar 11.-2 responses (within j, 25 11.-2 SFlJ/lOf> I'BMC or each other) to
the reference peptide and I to 2 or the variant pcptidcs within a sci (Figure 3.1.6). Variant
pcptidcs augmented 11.-2 responses relative to reference pcptidcs (> 25 more SFlJ/I Of>
I'BMC) in 9/ 111 cases in which an 11.-2 response was elic ited (Figure 3.1.7). As can be
seen in Figure 3.1.7 1\. 1\2-7 variants stimulated 11.-2 responses in 3 individuals . with
variant 1\2-7-2 responsible till' this response in two or these three responding individual s.
A2-Ciag-3 and A2-Ciag-6 stimulated 11.-2 responses in 112 11 and #131 respectively
(Figure 3.1.7 E) while 1\2-Flu-1 and 1\2-Flu-5 enhanced 11.-2 production in one IIIV-
individual (Figure 3.1.7 F). In all other peptide sets (1\2-11. 1\2-9 and 1\3-2) . exce pt 1357-1
and 1\2-11' in which no pcpt idcs induced 11.-2 production. only I variant per set
stimulated a stronger 11.-2 response relative to reference pcptidcs (Figure 3.1.7 B. C. D).
These results demon strate the ability or variant pcptidcs to enhance 11.-2 production
relative to reference pcpt idcs,
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Fi~ure 3.1.5 Co mparison of reference and variant peptide s timula tion of 11.-2
production I. I'BMC from l llVvi n lcc tcd and/or l llV vunin fcctc d individuals were tested
in a single test against one or more peptide sets for IL-2 production by ELlS I'OT assay.
Examples in which reference pcptidcs stimulated > 25 IL-2 SFU/ IO(' I'BMC more than
variants within their respective peptide sets arc shown. A positive response is at least 50
IL-2 SFU/ ]O(' I'BMC and at least twice background. The background was subtracted. lh c
li LA class I allele that presents each peptide set is highlighted in red and underlined.
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Figure 3.1.6 Comparison of reference and variant peptide stimulation of 11,-2
pruductiou II. I'BMC from l llV-infcctcd and/or l ll v -uninfcctcd individuals were tested
in a single test against one or more peptide sets for 11,-2 production by ELlSI'OT assay.
Representative examples in which reference and one or more variant pcpt idcs stimulated
within ::;25 11,-2 SFU/l(/' I'BMC or each other are shown. The variant pcptidcs that li t
this criterion are indicated by arrows. A positive response is at least 50 11,-2 SFU/ IO(,
I'BMC and at least twice background. The background was subtracted. The l Il.A class I
allele that presents each peptide sCIis highlighted in red and underlined.
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Figu re 3.1.7 C o m pa r ison of reference and variant peptide s tim u la tiun of 11,-2
production III. PBMC fro m IIIV-inlCctcd and/or IIIV-uninlCctcd individ uals were
tested in a single test against one or more peptide sets for IL-:2 production by 1:L1SPOT
assay, Results arc shown for peptide sets 1\) 1\:2-7 B) 1\:2-X C) 1\:2-9 D) 1\3-:2 E) 1\:2-Gag
and F) 1\:2-Flu, 1\ posit ive response is at least 50 IL-:2SFU/lOi> PBMC and at least twice
background, The background was subtracted, The IILI\ class I allele (hat presents each
peptide set is highlighted in red and underlined,
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We next examined the relationship between IFN-y and 11.-2 production regardless
ofwhe ther the reference or varian t peptide was better. worse or similar. In the majority or
cases (15I1X) 11.-2 responses correlated with IFN-y responses > 150 IFN-y SFUII u"
I'BMC (Figure 3. I.X). In 3 or 15 cases. 11.-2 produc tion was correlated to a low IF -y
response o r 150-300 IF -y SFU/ IOh I' lHvlC (Figure 3. I.X A; Appendix A). In 4 or 15
cases. 11.-2 production was corre lated with moderate IFN-y responses (300-700 IFN-y
SFU/ IOh I'BMC; Figure 3. I.X B; Appendix A) and in the majority or cases (X/ 15). this
response was correlated with high IFN-y responses (> 700 IFN-y SFUIIO(' I'BMC) with 4
or these Xcases exceeding 1500 IFN-y SFUIIOh I'BMC (Figure 3.1.XC; Appendix A). It
is important to note, however. that a strong IFN-y response is not always associated with
11.-2 production as there were man)' cases in which IFN-y response s were > 300 IF -y
SFLJIIOh I'BMC and no 11.-2 response was detected (Example #100 1 A2-Flu Figure
3. 1.9). In 311X cases 11.-2 production was not correlated with a high IF -y response
(Figure 3.1.9). For #230. variant A2-X-6 was the only peptide to induce an 11.-2 response.
Interestingly. it was also the only peptide that did not induce an IF -y response. In the
case or # IOOl.A2-Flu-3 stimulated a positive 11.-2 response while this same peptide did
not stimulate a positive IFN-y response. These results demon strate that IF -y production
is not always correla ted with 11.-2 production. however. 11.-2 product ion is generally
associated with high IFN-y responses and. thus. dual functional ity o r respo nding CDX' T
cells.
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Figure 3. 1.8 Relationship between 11.-2 and IFN-y responses I. I'BI'vlC from IIIV-
in fected and/or IIIV-uninfcctcd individuals were tested in duplicate and single lest lor
IFN-y and IL-2 production . respective ly. against one or more pept ide sets by ELlSI'OT
assay. Examples in which enhanced IL-2 production is correlated with high IFN-y
responses are shown. Representative examples in which pcptidcs generated A) < 300
IFN-y SFU/lO(, I'BMC B) 300-700 lFN-y SFU/lO(, I'BMC C) > 700 IFN-y SFU/lO(,
I'BMC and a positive IL-2 response is observed are shown. A positive response is at least
twice background and at least 50 IL-2 SFU/lO(, I'BMC or 100 IFN-y SFU/ IO(' I'IHvI C.
The background was subtracted (rom the single test value or from the average of the
duplicates. Duplicates were within 20'1<, or each other. The l ll.A class I allele that
presents each peptide set is highlighted in red and underlined .
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Figure 3.1.9 Relationship between IL-2 and IFN-y responses II. I'BI'vl C from IIl V-
infected and/or l llV-uninfcctcd individuals were tested in dupl icate and single lest lor
IFN-y and IL-2 production. respec tively, agai nst one or more peptide sets by ELlSI'OT
assay. Examples in which enhanced IL-2 production is not corre lated with enhanced IFN-
y responses arc shown. A positive response is at least twice background and at least 50
IL-2 SFlJ/ l(l I'BI'vl C or 100 IFN-y SFU/l Oh I'BMC. The background was subtracted
from the single test value or from the average or the duplicates. The duplicates lcll within
20%, or each other. The IILA class I allele that presents each pept ide set is highlighted in
red and underl ined.
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3.2 Evolution of IFN-y and IL-2 respon ses
IFN-y and IL-2 responses were tested by ELlSI'OT assay at 2-3 time points fix
several individuals as shown in Figure 3.2.1. In terms of IFN-y responses. the overall
magnitude changed over time. while the general specificity of these responses was
sustained (Figure 3.2.1 A). For subject #34. variants ;\ 2-7-1 and ;\ 2-7-2 stimulated the
same number of IFN-y SFU/lO(, I'BMC on 12/0 1/10 as the reference peptide. l lowcvcr, at
a later time point (2 1/10/10) these variants surpassed the reference peptide in terms of
IFN-y SFU/I (l I'BMC stimulation. This also occurred for #230 in that variants ;\ 2-X-1
and ;\ 2-X-2 showed improved antigenicity relative to the reference peptide on 20/oX/ 10
but not on 1X/ 12/09 or 06/0 1/11. The pattern of IL-2 responses was much less consistent
over time (Figure 3.2.1 B).;\s shown for #00 1 and #230. IL-2 was detected at j ust 1 lime
point. With regard to # 131. despite a similar pattern of IFN-y production at both time
points. there was a change in overall magnitude and specificity of 11.-2 responses. These
results show that CDXt T cell responses to reference and variant pcptidcs vary over time.
primarily in magnitude, but also in line specific ity.
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Fi~u l'e 3.2.1 Evulution of peptide-induced IF N-y and IL-2 resp on ses. I'Hi'vlC trom
l ll v- infcctcd and/or l ll v -uninfcctcd individuals were tested in duplicate and single test
1'01' IF -v aud 11.-2 production. respectively, against one or more pept ide sets at one or
more time points by ELlSI'OT assay. Examples or the variation or responses seen within
a given individual are shown lor A) IF -v and H) 11.-2. A positive response is at least
twice the background and at least 50 11.-2 SFU/ )Oh I'HMC or 100 IFN-y SFlJ/ IOh I'Hi'vI C.
The background was subtracted lrom the single lest value or from the average or the
dup licates. The duplicates fell within 20'X. or each other. The l ll.A class I allele that
presents each peptide set is highlighted in red and underl ined. The date o r the sample
used fore ach experi ment is indicated in the heading lore ach subject (DIMlY) .
X6
3.3 Refer en ce ami va r ia nt pcpt idcs s ti m u la te ove r fup pi ng subsets of ens' T cellx
Based on the differe nces observed between reference and variant pcptidcs in
terms or IF -yand IL-2 production. we next asked w hether re ference and variant
pcptidcs stimulated the same or different subsets or CDX' T cells. To address this
question. we performed addit ive ELlSI'OT assays in which I'BivtC from l ll v-i nlcctcd
individuals were tested in dupl icate for IFN-y production against refe renc e pcpt idcs.
variants previously identified that elicited an IFN-y response and a combination o r the
referenc e peptide with each or those lFN-y-inducing variants previously identified . Due
to the rarity and low magnitude orlL-2 responses. we did not perf orm this ex peri ment for
IL-2 production. This was done for 3 peptide sets: A2-7 (Figure 3.3.1 1\ ). ;\ 2-Gag (Figure
3.3.1 B) and ;\2 -X(Figure 3.3.1 C). lfd ilf c rcnt subsets or c nx ' T cells were respond ing
we would expect an additive response in which wells that received a combinatio n or the
refere nce peptide and the variant peptide would show a higher number or IF -y SFlJ/ 10"
I'BMC equal to the number or IF -y SFlJ/lO" I'BMC induced by the re fe rence peptide +
the number or IFN-y SFlJ/ 1of> I'BMC induced by the var iant peptide . This. however. was
not observed in any or the individuals tested. regardless o r peptide set used (Figure 3.3. 1l.
As shown in Figure 3.3. 1. the response observed in wells with both referen ce and var iant
pcptid cs was no grea ter than that observed in wells receiving these pcptidcs individually.
Although this experiment was only done lo r one individ ual per peptide set. it is likely that
it is the same subse t «rcns' T cells respondin g to all pcptidcs within a peptide se t tor all
individuals. T he re fore , d ifferen ces in the ability olrefcrcn cc and var iant pcpt ides to
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Figure 3.3.1 ){CSI'0Il SCS to comhinariuns of reference and variant pcpridcs. I'IHvlC from
l ll Vvinlcctcd individuals were tested in duplicate lor IFN-y production by [ US I'OT assay
against reference pcptidcs. variants previously ident ified that elicit a response and a
combination or the reference peptide with each or those variants previously identified.
Duplicates were within 20'X, o r eac h other. Duplicates were averaged and the backgrou nd
was subtracted. Results arc shown forpept ide sets 1\2-7. 1\2-Ciagand 1\2-X. lh c IILI\ c lass I
allele that presents each peptide set is highlighted in rcd and undcrlincd.
induce cytokinc production by CDX+ T ce lls arc like ly due to di fferen ces in TCR
recognition and signalling,
3..t A compari son of C UIl+ T cell pruliferariun induced hy re fe re nce and
hetcr uclitic pcpt id cs
The second aim of this project was to invcstigatc whether IL-2-inducing
hctcro clitic pcptidcs augmented pro li feration and differe ntiation of CDX' T cel ls relative
to re ference pcptides. Prol if eration was measured by C FSE dilution in which the parental
popu lation was designated C FSEhigh and each subsequent generation was designated
CFSE10\\ , PBMC from study participa nts were CFSE labelled, stimulated with reference
orhctcrocliticpcptidc.andcul turcd for 7 days in thc abscncc o f cxogcnous cytokincs, On
day 7. the ce lls were stained IllrC DXand analyzed by Ilow cyto mctry. Fourtee n reference
and hctcroc litic peptid e pairs were compared in this manner. lilcvcu o f the hctcrocliti c
pcptidcs stimulated similar or enhanced IL-2 respo nses by CDX' T cells compared to
refer ence pcptidc s (ELISPOT) while the remaini ng 3 had similar or enhanced IFN-y
responses. It is important to note . however. that Il)J'1 ofthcsc J pcptidcpairs(A2-7/A2-7-
I: #23 1). IL-2 production was not measured by ELiS POT assay due to a limited number
of cells. For another one o f these 3 peptide pairs (A2-Gag/A2-Ga g-3: 111( 5). IL-2
production was enha nced by the hctcroclitic peptide relative to the re ference : however. it
was Icss than 50 SF U/I 06 PBMC. In comparin g refere nce and hctcroc liiic pept ide pairs.
only pairs in which at least one peptide stimulated 2: 3'% prol iferation of CDX+T ce lls
X9
were considered . l'cptidcs were considered similar if there was :s20% difference in the
percent of proliferating CDX' T cells and \\CI"e considered better if there was > 20'%
difference in the percent prolifcrntion of CDX' T cells. Under these crite ria. the reference
peptide enhanced prulifcration of CDX' T cells relative to hctcrocli iic pcptidcs in 5/ 1 ~
cases (Figure 3.4.1). For /100 ) . 1\2-7 stimulated more CDX' T cell proliferation relative 10
1\2-7-2; however. the CDX' T cells that responded to 1\2-7 -2 underwent addit ional
rounds of division when compared to those who responded to 1\2-7. l Ictcroclitic and
reference pcptidcs induced similar CDX' T cell prol iferat ion in 5/14 cases (Figure 3.4.2)
while hctcroclitic peptidcs enhanced proliferation relative to reference pcptidcs in 4/1~
cases (Figure 3.4.3). These results show that hetcroclitic pcptidcs were similar or better
than reference pcptidcs at inducing CDX' T cell proliferation in <)j l ~ cases.
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Figu re 3.....1 Compa r ison of ens' T ccll prulifcratiun induced by reference and
hctcroclitic pcptidcs I. PBMC from study part icipants were C FS I ~ labelled and
stimulated in vitro with reference or hctcroclit ic peptide for 7 days and then stai ned fix
CDX and analyzed using flow cytornc try. The l Il.A class I a llele that presents each
peptide is highlighted in red and underlined. Gated 0 11CDXh i~h ce lls.
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l le teroclitie-Stimulated
Figure 3A.2 C om pa r ison of C DS+ T cell proliferation induced by reference and
heteroclitic pcptidcs II. I'BM C from study part icipants were C FS E labelled and
stimulated in vitro with reference or hctcroclitic peptide for 7 days and then stained I'll!'
CI) X and analyzed using flow cyiomc try. The IILI\ class I allele that presents each
peptide is highlighted in red and underl ined. Gated on C I)X h i ~h cells.
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Figu re 3....3 Compa r isun of ens' T cell prulifcratinn induced by reference and
het cruclitic pcptides III. I'B MC from study participa nts were CFSE labelled and
stimulated in vitro with reference or hcterocl itic peptide for 7 days and then stained for
CDS and analyzed using flow cytornctry, The 111.1\ class I allele that presents each
pept ide is highl ighted in red and underl ined. Gated on CDShigh cells.
J .S A co m p a r iso n of C US' T ccll diffcrcntiutiun and activat ion indu ced by
reference and hcl cruclilic pcptides
Differentiation and activa tion or CDX' T cells induced by reference and
hcteroc litic pcptidc s was measured by flow cyto mctry and compared betwee n pcptide s as
well as betwee n C FSEhigh and CFSEI" " CDX' T eel I populations. I'Bi'vlC from study
participan ts were C FSE labelled. stimulated with reference or hcicroclitic peptide. and
cultured for 7 days in the absence o r any exogenous cy toki ncs, On day 7. the ce lls were
stained 1'01' CDX. I'D- I. CC R7 and/or CD45 RA. Staining 1'01' intracellu lar perf orm and
cy tok ines ( IFN-y and 11.-2) was done after a 4 hour incubat ion with refe rence or
hctcroc litic peptide-pulsed autologous BLC L in the presence or Brcfcld in A. As shown in
Figure 3.5.1 A. - 50%. or CFSEhigh CDX+ T ce lls (range IX-71I%) expre ssed C D45 RA
whereas on ly - 10%. or C FSE I" " CDX' T cells (ra nge 0.6- 15'%) expressed this marker.
regardle ss or which pept ide was used fix stimulation (Mann-Whitney test. no significant
diffe rence). As shown in Figure 3.5.1 B. :SSIX. or CSFEhigh CDX' T cells (range 0.6-5%)
expressed I'D- I. regardle ss or which peptide was used for stimula tion . There was.
however . a differe nce in I'D-I expression between reference and hctcrocl itic pept ide-
stimulated CS FEI" " CDX' T ce ll populations. with - 35% or re ference-sti mulated ce lls
(range 3-52% ) expressing I'D-l and - 20% o r hctcroclitic-st imulatcd ce lls (range 5-39% )
expressing I'D- I. Th is difference was round to be statistically significant with a p value
eq ual to 0.0262 (one-tai led Student's Paired t test). No CC R7 was detected for CFS I:I" "
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or CFSEh i~h CDS' T cell population s when stimulated with either reference or hctcrocliti c
pcptidc s Idata not shown ).
As shown in Figure 3.5.2. ::: 5'10 of CFSEhi~h reference and hetcroclitic peptide -
stimulated CDS' T cell s (range 0.5-5%) expre ssed perform or IF -v , Pcrforin exp ressio n
was detected in 19%.of reference -stimulated C FSE1o" CDS' T cel ls (range 2.9-27%.) and
in 15'% of hctcroclitic -stimu latcd CFSE1o" CDS' T cells (ra nge 0-46'%) (Mann Whitney
test: No significant di fference : Figure 3.5.2 A). IFN-y was detected in 62'% of refere nce-
stimulated CSF I~I, "\ CDS' T ce lls (range 5-64 %1) and in 45'% o f hctcrocliti c-stimulutcd
CSFE1o" CDS ' T ce lls (ra nge 4.4-79'%) (Ma nn Whitney Test: No significant difference:
Figure 3.5.2 (3). Two individua ls were tested 11)1'11.-2 prod uction. however. less than 1%.
proliferation was observed 11)1' all but one peptide (data not shown). Given the small
sample size. the results do not oflcr a fair compari son between rcfc rcncc and hcterocl itic-
stimulated population s. These result s show that referen ce and hctcrocl itic pcpiidc s induce
expression of CD45RA. pcrforin and IF -y similarly « 10'% difference ). Reference
pcpt ides induced higher exp ression of I'D-I in C FSEh i~h C DS' T cells than hctcrocliti c
pcptidc s (35'% vs 20'%; p=0.02( 2). CFSE1o" CDS' T cell s expre ssed more I'D-I. pcrforin
and IFN-y than C FS Ehi~h CDS' T cells while the oppo site was observed 1111' CD45RA
expressio n. regard less of which peptide was used 1111' stimulation.
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F i~lI l'e 3.5.1 C om pa r isnn of C I>..5RA and 1'1>-1 expression Oil reference and
hetcrncl iric peptide-stimulated C FSE1u" and CFSE h i~h CUlt T cells. I' lHvlC were
stim ulated in vitro w ith re fere nce or hctcro cli tic pcp tidcs in the ab sence of exo ge nous
cy tokincs tor 7 day s and then sta ined for 1\) C D45RI\ o r B) I'D - 1 expre ssion and
an al yzed usin g llow cytomctry, Gated on C DXhigh ce lls, For C D45RI\ . the hori zont al line
throu gh the gro up repre sents the medi an frequ en cy. For I'D -I. the hor izo ntal line thro ugh
the g roup repre se nts the mean frequ en cy.
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Figu re 3.5 .2 C o m pa r ison of pcr fo rin a nd IFN-y cxprcssion in reference a nd
hetcruclit ic pc p tidc -s ti m u la tcd C FS E1o" a nd CFS E h i~h C I>S+ T cells. PBMC were
stimulated in vitro with ref erence or hctcrocl itic pcptidcs in the absence of exogenous
cytokincs fix 7 days. On day 7 ce lls. were incubated with refere nce or hctcroc litic
pept ide-p ulsed autologous BLCL in the presence o f brclcldin ;\ then stained IlH' A)
pcrforin or B) IFN-y expression and analyzed using flow cytornc try. Gated on C [) li h i ~h
ce lls. The horizontal line through the groups represents the median frequency.
3.6 A cumpurisnn of C DIl+ T cell cytotoxicity induced hy reference and
hcteroclitic pcptidcs
Hcforc proceeding to aims three and lour or this project, we lirst compared the
ability o r reference and hctcroclitic peptide» [0 generate CTL and used this data to
determine the appropriate eff ector to target ratio tor subsequent avidity and cross
reactivity assays. CTL were generated in vitro in the presence o r exogenous IL-7 and IL-
2 by stimulating I'BMC from study participants with reference pcptidcs. IL-2-inducing
hetcroclitic pcptidcs and/or variant pcptidcs that enhanced IFN-y production by CDX' T
cells. CTL activity was assessed between days Xand II by 51Cr release assay. using 51Cr_
labelled peptide-pulsed autologous or l Il.Avmatchcd BLCL as targets. The percent
specific lysis was calculated from the amount Or 51Cr present in the supernatant ofthe test
wells relative to the amount or 51Cr present in the supernatant o r the maximum and
minimum release wells. CTL from nine individuals were tested in this manner. One
individual (#43) was tested against A2-7 pcptidcs and A2-Gag pcptidcs. therefore, this
individual will be counted twice to give 10 cases. Two individuals (11001 and IIIX7) were
tested on two or more di ffe rent occasions and their CTL activi ty was diff erent each time,
therefore, two additional cases were added for a total o r 12 cases. In 4/12 cases. reference
peptide-stimulated CTL showed greater specific cytotoxicity than variant-stimulutcd CTL
at 3 or more o r the 4 eff ector to target ratios tested (Figure 3.6.1). In 7/ 12 cases,
reference- and variant-stimulated CTL had comparab le cytotoxic activ ity at 3 or more or
the effe c to r to target ratios (Figure 3.6.2; Appendix B). In all 7 cases this response was
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Figure 3.6.1 Comparison of CUS + T cell cytotuxicity induced hy reference and
heteruclitie pcptides I. Spec ific cytotox icity or ens' T ce lls stimulated in vitro with
reference or hcrcroclit ic pcptid cs was tested. in dupli cate. by 51Cr release assay against
reference or hctcrocl itic pept ide-pul sed (A) autologo us or (B) l ll.Avrnutchcd BLCL target
ce lls at increasing eff ector to target ratios. Duplicates 1\:11 within 20'rl. or eac h other. The
l ll.A class I a llele that presents each pept ide is highlighted in red and underlin ed. Tests in
which peptide-pulsed and non-pulsed BLCL were used as targets are indicated by black
triangles and blue squares. respect ively.
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Figure 3.(1.2 Cumpnr ison IIf C Ult T cell cytu tox icity induced by reference a nd
hetcroclit ic pcptides II. Spec ific cytotoxicity o r CD!!+ 'I' cells stimulated in vitro wirh
reference or hctcroc litic pcptidcs was tested. in dupli cate. by 51Cr release assay against
reference or hctcroclit ic peptide -pulsed autologous BLCL target cells at increasing
effe ctor to target ratios, Duplicates fell within 20'% or each other. The l ILA class I allele
that presents each peptide is highlighted in red and underlined, Tests in which peptide-
pulsed and non-pulsed BLCL were used as targets arc indicated by black triangles and
blue squares. respectively.
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< 12'y.,over background killing regardless of effector to target ratio with the exception of
#155 A3-2-stimulated CTL. which showed kill ing 20'y., over background at a 20: I
effector to target ratio. In 1/12 cases. hctcr oclitic pept ide-stimulat ed CT L showed greater
specific cytotoxic ity than reference-stimulated CT L at all eff ector to target ratios tested
(Figure 3.6.3). Many of these experim ents exhibited high background . maki ng it difficult
to draw linn conclusions regardin g enhanced perform ance of variant pcptidcs, howe ver,
based on these result s reference pcptide s were generally more effe ct ive at stimulating
peptid e-specific CT L than variant pcptidc s,
3.7 Evo lu tio n orcrt. resp onses
As shown tor cytok inc and prolife ration responses. CT L responses also varied
over time. Reference and variant-stimulated CT L were tested by 51 Cr release assay
against reference or hctcrocl itic pept ide-pulsed autologous BLCL target ce lls at 2-3 time
points lor two individuals (#00 1 and #187) as shown in Figure 3.7.1. For #00 1 (Figure
3.7.1 A). IL-2-indu cing peptid e 1\2-7-2 stimulated CT L with much stronger peptide-
specific cytotoxic ity (~30'y., specific lysis over background at all effec tor to target ratios)
than A2-7-stimulated CT L (no kill ing over background) on 10/08/09 and on 17/02/10 .
l lowcvcr, 6 month s later on 30/08/ 10 these respon ses were reversed with A2-7
stimulating ~ 20'y.,specific lysis over background and 1\2-7-2 stimulating no killing over
background . For #187 (Figure 3.7.1 B). A2-7-stimulated CT L killed 1\2-7-pu lsed BLCL
with an effic iency o r ~ 10'1. over background on 29/03/ 10 while 1\2-7- I-stimulaled CTI.
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Fi!-:urc 3.6 .3 Co mpa rison of ens' T ccll cytotmicity induced hy rcfcr cncc and
hctcroc1itic pcptidcs III. Specific cytotoxici ty or CDX+ T cells stimulated in vitro with
referen ce or hctcroclit ic pcptidcs was tested. in dupli cate. by 'ICr release assay aga ins:
reference or hctcroc litic peptide-pul sed autologo us BLCL target ce lls at increasing
effector to target ratios. Duplicates fclI within 20%.o r each other. The IIL/\ class I allele
that presents eac h peptide is highlighted in red and underl ined. Tests in which peptide-
pulsed and non-pulsed BLCL were used as targets are indicated by black triangles and
blue squares. respecti vely.
107
oj ::.~Ie:
Effector:hrgetR.tto
A) '001A2·7-5timulatedCTL
HLAA1, A2,BI3,BI8
17102110
#0(1
A2·7·2-5t imlllatedCTL
HLAA1. ~B13.B18
~---::::: _ 17/02J 1O + A2 7 2~~ -.- 10/08109 + A2 7 2.~:-: ~.=; :=
Effector:Tuget Riltio
#001
A2·7-5timulatedCTL
HLAA~ott8/~~3.B18
l~--~·;ePbde
~ ..-------
1
J' ~
o 6 10 15 20 25
Enector:T.rgetR atio
#(01
A2·7·2-5tin ,ulatedCTL
HLAA~~ i,~~3,B1B
~ -~ "k~-:
Etfeetor:;argetRatio
~ =:~.
Effector:TargetRatio
B) .187A2·7-5timula'edCTL
H~o:'ioB14
#187
A2·7·1-5t imulatedCTL
HLA2~:'ioB14
i~ -·:~·
Effector :TargetRatio
#187
A2·7-5tlmulatedCTL
HLA1~1:'ioB14
' -8 7
A2·7·1-5t i. ,ula'edCTL
HLA1~:'ioB14
k:~.~"
Effeclor :"ar getR atio
lOS
Figure 3.7.1 Evolution of peptide-induced CTL responses. Speci fic cytotoxici ty or
CDS' T cells stimulated in vitro with reference or hctcroclitic pcptidcs was tested. in
duplicate. by 51Cr release assay agai nst reference or hctcroclit ic pept ide-pulsed
autologous BLCL target cells at one or more time points. Results arc shown 1'01' A) 1100 1
and B) 11 187. Duplicates ICiI within 20'% or each other. The l ll.A class I allele that
presents each peptide is highlighted in red and underlined. lc sts in which peptide-pulsed
and non-pulsed BLCL were used as targets arc indicated by triangles and squares.
respectively. The l ll.A class I allele that presents each peptide set is highl ighted in red
and underlined. The date or the sample used for each experiment is indicated for each
subjed (D/M/Y).
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killed A2-7- I-pulsed BLCL with an cffic icncy j; 10%,over background on the same date .
l lowcver. on Il)/l 0/10 ncithc rA z- ? nor A2-7-I- stimul ated CTL were capable or killing
peptide-pul sed BLCL by > 5'y., over background regardle ss or effect or to target ratio.
These result s show that ens' 'Lccll respon ses to reference and variant pcptid cs vary ove r
time in both magnitude and general specificity.
3.8 A comparison of TClc/pcptidc-H LA class I interaction avidity of reference
and hctcroclitic pcptidcs
The third aim or this project was to measure TCk/pcptidc-l ll.A class I interac tion
av idity or IL-2-inducin g hctc rocliti c Ill Y pcpt idcs relative to index pcpt idcs,
TC R/pcptidc-IILA class I avidity was determ ined by ) I Cr release assay in which
autologous (or l ll.Avmatchcd) BLCL were pulsed with diluted concen trations or peptide
and then used as targets for reference and hctcro clitic peptide- stimul ated CT L. The
appro priate effec tor to target ratio. one that allowed the highest kill ing over background
at the lowest ratio. was determined from the previously described cytotoxici ty
expe riments. TC k /pc jui dc-l ll.A class I avidity was estimated as the co ncentration or
peptide at which the percent speci fic lysis ralls to 50% or the maximum . The av idi ty 01'4
pcptidcs was determin ed using this method as shown in Figure J .li. l. As can be seen in
Figure s.s.: i\. A2-7 has ~ 1 0 rold higher av idity than A2-7-2. A2-Flu and A2-F1u- L
however. have more co mparable avid ities at ap proximately I pg/ml eac h (Figure J .li. 1
B). These result s show that hctcrocl itic pcptide s arc not necessarily higher av idity
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F igu re 3.N.1 C om pa r ison of reference and hctcroclitic peptide T CR /pcptidc-IILA
cla ss I avidity. CT L we re st imulated in vitro with reference or hct c rocl it ic pcptidc s and
tested . in duplica te . by 51C r release assay aga inst d ilu ted co nce ntration s or refere nce or
hctcro cliti c peptide-pul sed (A) auto logo us or (B) l ll .Avrnutchcd BLC L tar get ce lls.
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pcpt idcs tha n rcfcrcncc pcptidcs .
J.lJ A comparison of reference and hetcruclitic pcptide-stimulutcd-C 'I'L
rea ctivity
The fourth and fin al aim of this pro ject was to test the ability of IL-2-indueing
hctcroclitic IIIV pcpt idcs to generate broadly reactive CTL. Cross-reactivity was
determined by 51Cr release assay in which autologous or l llAvmatch cd I3LCI. were
pulsed with each peptide in the entire peptide set. CTL were added at an appropriate
effector to target ratio determ ined from the previously described cytotox icity
experiments. The abi lity of re ference and hctcroclitic peptide-stimulated CTL to kill
I3LCL pulsed with the entire peptide sci was then compared . CTL trom 7 individ uals.
stimulated against the re ference and up to 3 other variants within the respective peptide
sci. were tested in this manner. Three representa tive example s arc shown in Figure 3.9. 1
and the remain ing arc shown in Appendix C. In 6/7 cases. refere nce and variant pcptidcs
showed comparable breadth ofreactivi ty and magnitude of response « 10% spec ific lysis
in d ifference ) . For 1/100 1 (Figure 3.9.1) and 1/43 (A2-7 sci: Appendix C). the ref eren ce
peptide was marginally better in terms of magnitude of response « 10%. differe nce from
hctcroclit ic peptide-stimulated CTI.). For 1/155 (Figure 3.9.1). 11 174 (Appendix C). IIIX7
(Figure 3.9.1) and 1143 (A2-Gag sci: Append ix C). the heteroclitic peptide was marginally
better in terms of magnitude of response « 10%, diffe rence from re ference peptide-
stimulated CTL). 11 155 A3-2-3-stimulated CTL were better at killing A3-2- I-pulsed
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Figure 3.9.1 Compa r ison of reference and hctcrnclitic pcptide-sf imulntcd-C'I'L
reactivity. CTL were stimulated in vitro with reference or hctcroclitic pcptidcs and
tested. in duplicate. by :<ICr release assay against BLCL pulsed with each peptide within a
set. Duplicates fell within 20'Yo or each other. The l ll.A class I allele that presents each
peptide is highlighted in red and underl ined. The effec to r to target ratio used is indicated
below each heading.
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BLCL than A3-2-stimulated CTL by a 2 lold difference, however. still less than IO'Y..
difference overall (20% vs 11% over background . respec tively). 1100 1 (Appendix C) was
the only individu al who showed greater overa ll killing by hctcroclitic peptide -stimulated
CTL than reference peptide-stimulated CTL simply beca use the refere nce peptide did not
stimulate CTL. A2-7-2-stimula ted CTL trom 1100 I. however . only recogni zed 1\2-7-2-
pulsed BLC L and A2-7 -pulsed B cel ls. Interestingly. two individuals. 11 155 (Figure 3.1.9)
and 11 174 (Appendix C). showed stronger killing aga inst A3-2-pulsed BLCL than 1\ 3-2-3
and A3-2-4 BLCL. respectively. However. the differen ce between these two response s
was still < 10'Y.. specific lysis difference. These results show that reference and
hcicroc litic peptide-stimul ated CTL had similar breadths or reactivity with hctcroclitic
pept ide-stimulated CT L being slightly bette r in 5/7 cases.
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Chapter " Discu ssi on
In thi s s tudy . we identified l) IL-2-in d uein g hc tc roc li tic var iant s o f 6 d if ferent
111.1\- 1\2 and 1\3 - res trict ed C T L cp itopcs of IIi V a nd influenza o rigi n. I lctcroclitic
pcp tidc s we re cre a te d by making co nse rva tive and se m i-co ns e rva ti ve subs titutio ns a t
a mi no aci d po sit ion s 3. 5 and 7 0 f re k re nee pcptidcs , Co ns is te n t with th e s tudy by Se tte
(' I al. Illi lil we found th at hcicro clit ic pcptidc s arc fairly common as hctcrocli tic va ria nts
we re identi fi ed from 6 of li peptide sets tested (Table 2.<J.I ). I\mon gst the l) hctc rocl it ic
pcptidcs wc identified , no positi on (3. 5 or 7 ) or typ e (eon se rva tiveo r se m ieo nse rva tivc)
of ami noaeid subs titu tio nwaseo ns is te nlly l; lvo ured .
". 1 ld cnt ifi ca t inn IIf IL-2-indurin ~ hct crncl it ic p cpt id cs
T he fi rst ai m of thi s s tudy wa s to ide ntify pe pt idc s that se lec tive ly augme nte d 11.-
2 production by l l lV-spc ci fic ens' T ce lls re la tive to index pc pt idcs . A s expe c ted . 11.-2
responses we re mu ch less Irc q uc n t than IF -y re spo nses (Ta b le 3 . 1. 1). Var ian t pe pt ide»
ca pa ble of au gmenting 11.-2 producti on (b y > 25 11.-2 SF U/ IO" I'B ivIC ) rel a tive 10
refe re nce pcpt idcs occ ur red in 50%. (l)!l li) o f ca ses in whi ch a n 11.-2 resp on se was
o bse rved ( Fig ure 3. 1.7 ). Inte rest ingl y. va ria nt pcpt idcs less frequ entl y aug me nted IFN-y
resp on se s (b y > 100 SF lJ /IO " I'I HvlC ) re lative to reference pcp tidc s, Thi s occ urre d in less
th an 25 '1., ( 13/60) o f ca ses in w hich an IFN-y res pons e was o bserved ( Figu re 3 . 1.4 ). In
te rm s o f IFN- y pro d ucti o n. the maj ori ty o f va ria nt pcpiidcs produ ce d a lesser res pon se
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than that observed with the reference peptide (Figure ] .1.1). This indicates selective
enhancement o r signaling pathw ays I,JI" the produ ction or 11.-2 rathe r than IFN-y by
hctcroclit ic pcptid cs. Based on these results. we considered what aspects or a variant
pept ide might make it better or worse than the reference peptid e.
Ultimately. hctcro clitic act ivity is depend ent on orientation o r peptid e side chains
that interact with the CDR] regions o r the TCR in the pMII C:TCR complex .
Unfort unately, we were not able 10 model the specific pMII C:TCR interactions and we
did not sequence the TCRs or the responding CDX' T ce lls. therefore, we can' t
definitively state why some changes enhanced or abroga ted TCR recogniti on . l Iowcvc r.
by simply com paring the side chain characteristics or the amino acid substitutiou in the
varia nts to those or the reference peptid cs, we can speculate on reasons why certain
amino ac id enhan ced responses and others abro gated responses, For exa mple. co mparing
peptide 1\2-7 with its variant 1\2-7- 1. there is a conservative change from valine to
leucine at position ] Crable 2.6.1). Both amino ac ids possess hydroph obic side chains but
the side chain o r leucine is one car bon bond longer and less hydroph ob ic than that o r
valine based on the Kytc and Doolittle scale o r hydrophobi city 12051. It is possib le that
due to its less hydrophobi c nature . the side chain or leucine is orient ed more towards the
TCR than that or valine. enhancing TCR recogniti on . Given that 1\2-7-2 enhanced 11.-2
production relative to 1\2-7 and 1\2-7- 1. and that the change here at pos ition ] from
valine to threon ine. is again a change to a less hydroph obic side chain. this effec t co uld
be somewhat genera lized. Interestingly. changes made at position 7 in 1\2- 7 lrom
histidine to glutamine (1\2-7-5 ) or histidine to arginine (1\2-7-6) abro gated the IFN-y
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respo nse o bserved w ith A2-7 in a ll 7 respo nd ing indi vidu al s. T hese cha nge s likel y
abroga ted the respo nse becau se we rem o ved an a ro ma tic ring that may inte ract in a
specific pocket o r the T C R. The se explana tio ns how e ver . re ma in spec ula tive . G ive n that
the enha nced respo nses o bserve d to ce rtai n pcptidcs we re not univ e rsa l. we can not be
sure how ce rta in pcpt idcs interac t w ith ind ividu al T CR s w ith out e ithe r seq ue nc ing the
TeR to properl y pred ict th is inte racti on o r purif yi ng the pMII C: T C R co mplex . Th e
ex plana tio ns g ive n here may hold true lo r these part icul ar pcpti dcs a nd respo nd ing
ind iv id ua ls. but the same ch ange s in o the r pc pt idcs a nd in othe r ind ivid ua ls may have
o ppo site e ffec ts.
An interesting feature o r so me o r the hcicro clit ic pc ptid cs we identified is their
abi lity to se lective ly e nha nce 11.-2 prod uction ov er IFN- y pro du ct ion by C DX' T ce lls .
l lc tcroclit ic pcptidcs that enha nce d IL-2 product ion on ly e nha nce d IFN-y produ ct ion
relat ive to thei r resp ec ti ve reference pept ide in 3/9 case s. Inter es tingl y. how e ver . 11.-2
respo nses were as soc ia ted with IFN-y resp on ses > 150 IFN-y SF U/ IO(, I' lHvlC (F igure
3. I .X) in the maj ori ty o r cases (X/9 hct crocliti c peptid e case s. I SIIX tot al case s ). In o nly
1/9 hctcro c litic pe ptide case s (3 / 1X total ca ses) the 11.-2 respo nse di d not co rrela te w ith
high IFN-y res po nse s ( Fig ure 3. 1.9) . Th e most inter est ing o r these 3 cases occur red in
sub ject 1123 0 in w hich there was no IFN-y respo nse to pept ide A2-X-6 (ob se rved in X
o the r par tic ipa nts as well ). but it wa s the o nly pe ptide in the en tire set to el ic it an 11.-2
resp on se in th is indiv id ual. Unfo rtunate ly, we o nly dete c ted 11.-2 at one o r three tim e
point s tested for thi s subject (Fig ure 3 .2 . 1). l lo wc vc r, it is worth notin g tha t the o ve ra ll
magn itude o r IF N-y resp on ses wa s significantly high er at the tim e po int wh en 11.-2 was
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detected than at all other time points. This may indicate a decrease in the functional
capabilities of the CDX' T cells that recognize this peptide in subject 11 "230 and explain
why IL-"2was onlydded ed at the earl iestt imepoinl.
Although it is unusual. we arc not the fi rst to report such a phenomenon. Using a
dual color ELlS I'OT assay capable of simultaneously detecting IFN-y and IL-"2secreting
cells. Ndongala ('/ al. 1"2061 characterized respond ing CDX' T cells by their ability to
secrete IFN-y. IL-"2 or both in response to the whole IIIV protcomc. Although the
majority of CDX' T cells produced IFN-y alone (77.7''10 acute infe ct ion early disease
(AIED). XX .9'Y., chronic disease) or IFN-y and IL-"2 ("21.I'X, AIED. 10.X% chronic
disease). CDX' T cells secreting only IL-"2 were rarely reported (1. 17% AIED. 0."2%
chronic disease). For A"2-X-6. the change from a tryptophan to arginine al position 7
replaces a large indole functional group with a positively charged side chain of amino
groups. It is possible that the TCI{ thaI recognizes A"2-X-6 has anionic residues at this
contact site and that the interaction between this pept ide and the TC I{ was enhanced by
the cationic charges and hydrogen bonding properties of the arginine residue. nut how
changes in peptide structure such as those in our hcic rocl itic pcpr idcs enhance IL-2
production and di ffere ntial ly alter IFN-y production by CDX' T cells relative to reference
pcptidcs is unkuown.
Hascd on the diff erences observed between refere nce and varian t pept ide» in
terms of their abilities to stimulate IFN-y and IL-"2production by CDX' 'L cc l ls. we tested
whether these pcptidcs stimulated the same or dif f erent subsets of CDX' T cells. Using an
additive ELlSI'OT approach. we dete rmined that the same subset of CJ)X' T cells
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responded to the reference and variant pcptidcs in peptide sets 1\2-7. 1\2-X and /\ 2-Ciag
(Figure 3.3.1). Given that we did not alter the IILI\ -binding properties or the hetcrocliti c
pcptidcs relative to the reference pcptidcs. these results are not surprising. This suggests
cross-reactivity or respondin g CDX+ T cells rather than differential recognition or
reference and variant pcptidcs. The ability or variant pcptidcs to stimulate the same
subset o r CDX' T cells has important implications in this study, This indicates that
di ffere nces in IFN-y and 11.-2 induction by reference and hctcroclit ic pcptidcs are due 10
di ffe rences in intracellular signalling within the responding CDX' T cells. Salazar ('/ al.
12071 reported increased tyrosine phosphorylation or TCI{signaling proteins 1 /\ 1'-70 and
TCI{ C, chains in hctcroclit ic peptide-stimulated CTL compared to re ference peptide-
stimulated CTL. BUI beyond this. lillie is known abo ut the structural and signaling
mechanisms involved in hcteroclitic activ ity.
4.2 Cu m pa r isnn of reference and IL-2 -indueinl-: hetcroclitic pcptides driven
prulifcratinn and differentiation
11.-2 secret ion by CDX' T cells is important lor proliferation and differentiation
into effector CDX' T cells in the absence o r CD4' T cell help 120XI. In this study. we
expected that pcpt idcs thaI enhanced 11.-2 production by CDX' T cells would also
enhance prolifcr.uion and diff erenti ati on or these respond ing cells. Using CFS I ~ dilut ion
and llow cytomc try. we compared 14 reference and variant peptide pairs till' their ability
to stimulate proliferation o r CDX' T cells. or these 14 pept ide pairs. 6 included 11.-2-
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inducing hctcro clitic pcptidc s and 3 included variant pcpt idcs that enhanced IFN-y
product ion relative to their respect ive referenc e pcptidc s, Unex pectedly. of the 6
hctcroclitic pcpiidcs tested . 2 pcpridcs did not stimul ate anyprolircration.1 pept ide
stimulated a similar amount ofprolif cr.uion as the refere nce pcptide. I peptide stimulated
less prol i fcrution than the referen ce. and only 2 pcptid cs enhanc ed prolife ration o f CDX'
T cells relative to reference pcpt idcs, Interestingly. two of the variant pcpt idcs that
enhanced IFN-y produ ction (;\ 2-7- 1 in #23 1 and ;\ 2-Gag-3 in #1( 5) also enhanced
pro liferation of CDX' T cells relative to ref erenc e pcptidcs (Figure 3.4.3). Although we
expec ted all of the 11.-2 inducing hctcrocliti c pcptid cs to enhance prol ife rat ion o f CDX' T
ce lls. a complicating factor is that there were o ften large gaps o f time (up to I year + )
betwee n initial 1 ~L1 SI'OT experiment s and prol ifcrari on assays due to a lack of avai lab le
I'BMC samples for a given subject. T here fore. it is possible that the CDX' T cells
recognizing the hctc rocliti c pcptidcs became ex hausted or lost their ability to produce 11.-
2 during this time. It is also possible we observed a similar phenomenon as l lcuth ('/ il l.
12091 who reported that while 11.-2 production from the total l llV-spccific cm:' T ce ll
popul at ion docs correlate with prol iferat ion , routine detection o f both 11.-2 product ion
and pro lif eratio n from the same antigen-speci fi c CDX' T cells is rare. Their stud)
suggested that distinct populations of CDX' T cells exist - those capable of proliferat ion .
those with the ability to produce 11.-2 and lew with dual capacity. We only tested lor Ll>
2 production and proliferati on by now cyto mctry for 2/ 14 peptid e pairs and in both cases.
less than I'rl.prolircrat ion was observed (data not shown). thc rcf lre. we cannol makea
lair com parison to the result s of l lcath ct il l. 1209j. However. it is possib le that our
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hctcroc litic peptide» still induced IL-2, but the remaining proliferative subpopulation was
Iunctionally exhausted and unable to proliferate.
Differentiation and activation or CDX' T cells induced by reference and
hctcroclitic pcpt idcs was also measured by flow cytomctry and compared between
pcptidcs as well as between CFSEII>" and CFSE high populations (Figures 3.5. 1 and 3.5.2).
CDX' T cell populations arc characterized by the expression or part icular cell surface
markers such as CCR7. CD45R;\ and CD2X 1197, 2 101. In this study, we proposed that
hctcrocliiic pcptidcs selectively stimulating IL-2 producing CDX' T cells may either be
selectively recognized by. or selectively drive the generation or CDX' Tn l. The Tnt
lineage is characterized by the CDX'C IN5R;\-CCR7 'C D2X' phenotype whereas the TI ~I
lineage is characterized by the CDX' CD45R;\ ' CCRT CD2X- phenotype 1197. 2 10 j. Naive
CDX' T cells arc characterized by a CDX'CC R7'CD45R;\ ' phenotype 1210j . By llow
cytomctry. we assessed expression or CDX, CFSE. and appropriate fl uorochrome
combinations or CD45R;\ . con, pcrforin, I'D- I. IL-2 and/or IFN-y. No CC R7 wax
detected II II' CFSEII>" or CFSE1IIgh CDX' T cell populations when stimulated with either
rcli:reneeor heteroelitiepeptides. For both rcli:renee and hcteroelitic peptide-stimulated
cultures, ~5 0'y., or CFSEhigh CDX' T cells expressed CD45R;\ whereas only ~ I O 'y., or
CFSEII>" CDX' T cells expressed this marker (Figure 3.5.1 A), Given that the prolifcruting
CFSEII>" cells express a CDX'C D45R;\ II>"CCRT phenotype and have a higher proportion
expressing the effec tor molecules pcrforin and IFN-y (Figure 3.5.2), our pcptidcs (both
reference and variant pcptidcs) appear to mainly stimulate TI ~l populations. This is
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co nsistent with other studies thai lound a typical phenotype or IFN-y-producin g.
prolifcrntin g effector cells to he CD~S RI\ -/I""CCRT II SS. 20X.2 111.
I n t~ r~s t i ng l y there was a significant difference in the expre ssion or I'D-I (one
tailed paired z tcst, P = 0.02( 2) between the CFSEI"" reference and hctcrocl itic- stimul atcd
population s (Figure 3.S.1 B). This phenomen on was observed Ill!' pcptidc s 1\2-7-1. 1\2-7-
2. 1\2-Ciag-3. 1\2-Ciag-S. 1\2-F1u-l . 1\2-F lu-3 and 1\2-F lu-S. with pcptidc s 1\2-7-1 and
1\2-Ciag-3 each stimulating this effec t in two individ uals while the remainder stimul.ucd
this effect in one individual. I'D-I has been highli ghted as a major factor in T cel l
exhaustion in IIIV infection 1212-2141. When T cells beco me ex hausted. they can no
longer proliferate or secrete cyto kincs and they lose their cyto lytic capabi lity. ultimately
leading to i ne ffe ctive immune respon ses and an inability to clear virus. Stud ies in both
humuns and mice 12 12. 2 13. 2 1S1 have shown that blocking the I'D- III'D-L1 patlmay
restores the capacity or exhausted CDX' T cells to unde rgo prolifc nuion. cytokinc
producti on and cytotoxic activity. restoring their protective funct ion and reducin g viral
load. Our C FSEI"" hctc roclitic peptide -stimulated CDX' T cells showed reduced
ex press ion or I'D- I (20%.) relative to CFSEI"" reference pep tide- st imulated CDX' T cells
(:>S%.) supporting a possible therapeutic role Ill!' these pcptidcs in reducin g I'D- I
expression on stimulated ce lls and decreasing T c~ 1 1 exhaustio n, Other factors besides
I'D-l may also contrihutc to the exhausted phenotype or l llV-spcci fic C DX' T cells.
Inhibitory recep tors such as 2B4. 1.1\( ,-3. CDI(10 and T IM-3 arc also uprcgulatcd on
virus-specific C DX' T cel ls (re viewed in 1216 1l and. as one migh t expect . the more such
receptors these cel ls accumu late. the more exhausted they become. Unfortunate ly. we did
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not compare expre ssio n of other marker s of exha ustion. but based on the observed
downrc gulation of I'D- I and enhanced ability to produce 11.-2 by respondin g CDX' T
cells. it' s possible that hctcrocl itic pcpt idcs also downrc gulatc other inhibitory receptor s,
This is a novel and potentially significa nt finding that bears further investigat ion,
Method s to selectively recru it T cel ls with lesser eviden ce of functional or phenotypic
exhaustio n using therape utic vaccine s may be rclcvunt Ior a number of chronic infectio ns,
-t..' C om pa ri son o f reference a nd hetcrocl it ie pcpt id c:II LA class I:T CI{ av id ity
Aims three and limI' of this project were to com pare reference and 11.-2-inducing
hctcroclitic pcptidcs in tcrms ofpl Il.A class I:TCR interact ion avidity and the ir ability to
generate broadl y reactive Cl L. In the major ity of cases (7/12 total cases tested) .
reference and variant pcptidc s stimulated similar amount s of cytotox ic activity (Figure
3'cl.2). wherea s 11.-2-inducing hctcrocli tic pcptidc s stimulated higher cytoto xic activity
than reference pcptidc s in only I case (Figure 3.6.3). In studies emplo ying hctcroclitic
cancer pcptidc s. these pcptidc s broke T cel l tolerance and dramaticall y augmented cel l-
mediated immunity against tumor-associated antigens II XX-I l)0l . I:nhanced anti -tumor
immunity dr iven by these pcptidcs was at tributed to increased stability of the
pMII C:TCR complex. which resulted in increase d avidi ty and residen ce time of the
co mplex 1\921. Our hctcroclitic pcptidcs. however. did not stimulate stronger cytotoxic
respon ses than reference pcptidc s and were not of higher avidi ty than reference pcpi idcs
(Figure 3.X. I). Selle ct al. II XXI reported hctcrocl itic pcptidc s that produced up to 107_
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fold increase in 'I' ce ll se nsitivity. Our results do not reflect thei r obse rved dramatic
increa ses in avidi ty. Th is may be due to diffe rences in methods for measur ing avid ity -
we used a Cr51re lease assay whereas they measured the level o f competition induced by
the test peptide for bindin g o f a radio lubc lcd standard peptide to purified 111.1\-1\2
mo lecule s. Takahash i e1 al. 12171 reported a co unter-reg ulation o f cyto lytic activity and
cytok inc prod uctio n in l llV-spcc ific mur ine C I)X' CT L by free antigenic peptide. The y
showed that treatment o f CT L with their cpi topic peptide resulted in a significant
reductio n of gran zymc B act ivi ty and mRNI\ exp ressio n of granzymc Band pcrfori n.
l lowcvcr, when the level of cytolytic activity was the lowe st. they dete cted maximum
amount s of cytok incs 11.-2. IFN-y. tumor necrosis fact or (T NF)-u . and macroph age
inflammatory prote in (M II')- If) in the cu lture supernatant. Theref ore. whi le our pc piidc s
enhance cyiokinc prod uction . they may have an inhibitory effect on cyto lyt ic activ ity.
Thu s 51Cr-release assays may unde resti ma te av idi ty in some cases.
It is also possible that hctcrocliti c activity is not as de pendent on av idity as others
have suggested. One key differe nce between our study and previous hctcrocl ir ic cance r
pept ide stud ies II X9. 190. 192jthat may also explain why avidity docs no t seem to play
as much of a role in our study is the dif f eren ce in the immunogcn icity of the refe rence
pcptidc s. In hctcrocl itic cancer peptid e stud ies . the reference peptide » were poor ly
imm unogenic to begin with as they were o fte n a ltered form » of sclf-pcptidcs. The self-
reac tive CT L that wo uld recog nize suc h pcptidc s arc typica lly deleted du ring 'I' ce ll
select ion resulting in the persistence o f on ly low avid ity 'I' cells. l lowcvcr, in our study.
reference pcptidcs were initia lly identified because they were known opt imal CTL
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cpiiopcs and thus, 1lI0r.: immun ogen ic than the reference pcptidcs or hctc rocli tic cancer
peptide studies , Perhaps our hctcroclitic pcptidc s do enhance T cdl sensitivity. hut at a
level undetectable by our methods or simply stabilize and enhance the reside nce time or
the pIILA:TC R interact ion in SO Ill': other way 10 allow activa tion or alternate signalling
pathways within the T cell. The fact that our study populat ion was suppressed on
IIA/\R T could have also limi ted our ability to detect CT L r.:spons.:s. Although our
hctcroclitic pcptides do not stimulate higher-avidity CT L. they may stimulate production
o r various other cytoki ncs. for which we did nol screen. that activate var ious other cell
populations. It is a lso important to note that CT L responses varied drnnuuicully over time
(Figure 3.7.1) as did cyiokinc (Figure 3.2. 1) and proliferation responses (not shown ). l lad
all expe riments been done at the SW Il ': time points. uhc observed results llIay have been
di fferent.
4A l letcroclitic pcptidcs stimulate h ruad ly reactive CT L
Zirlik ct ul. 11901argue that in order for a pept ide to he hctcro clitic it must not
only hypcrstim ulatc T cells and generate high avidi ty interactions. hut must a lso be able
to prime T cells to undergo ex pansion and further activation driven by the lowe r avidity.
rcli:r.:nccp.:pt id.:.Th.: hd.:mclitic p.:ptid.:s id.:nlili .:di n this study had silllilaravidi ti.:sto
the reference pcptides hut interestingly, hctcrocli tic-pcptid c stimulated CT L had slightly
better breadths or reacti vity in 5/7 cases tested (F igure 3.1.(» . In two indiv iduals. 11 155
(Figure 3.1.9) and 11 174 (A ppendix C). hctcroc litic peptide-stimulated CTL showed
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stronger killing against re ferenc e-pu lsed BLCL than bctcro clitic-pulscd IILCL. As both
li lY and Flu exist as many viral quasispccics within a single individual 162. 2 1XI. the
ability of hctcrocl itic pcpt idcs to generate broadly reactive CT L is a desired featu re for
therapeutic vaccin at ion. The fact that we identified several pcpt idcs that were broad ly
react ive in this sense is quite prom ising for this app roach as such pcpt idcs are ca pable of
activating CT L 10 react against multiple variations of that peptide within a given host.
.t.5 Hct crn clitic Ill Y pept id es and their pot enti al in therap euti c lil Y vacc ines
Consistent with the study by Scu c e/ al. I IXXI. we fo und that variant pcptidc s with
hctcrocliiic activity were fairly comm on. These result s are qui te encour aging Ill! ' the
discovery of additiona l hctcroclitic Ill Y pcptidc s, especi ally conside ring that only six
variants were made from each reference peptid e by substituting on ly one am ino acid at
eac h position. Given the vast array of standa rd and non-standa I'd amino acids that exist.
many more variants cou ld be generated and tested Il l!' hctcroclit ic propertie s. In additi on.
hctcroclitic pcptidc s could be generated by makin g substitutions at multiple position s
within a pept ide. given that the individual substitutions resu lt in enhanced TCR
recognition. It is a lso important to note that the hctcroc litic pcptidc s generated in this
study were variants of an already immunodominant peptide. We would be more likely to
observe differences in pIILA:TCR avidit y and differen ces in protectiv e pote ntial betwee n
variants and the referen ce pept ide if the referen ce peptide was less immun ogeni c to begin
with. as it is with hctcroc litic peptide cancer vaccines. Obviously. generating potentia lly
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hctcroclitic pcptidcs using pcptidcs that arc not normally well presented to the immune
system could he a tedious. laborious and costly process. However. this approach could
lead to CTL recognition or new cpitopcs and could stimulate new subsets or T cells that
otherwise would not be activated . This approach may be further improved by focusing on
conserved antigens. such as those in Gag. Chen e{ at. 11451 round that l llV controllers
were better able to inhibit viral replication through targeting or the immunodomi nant
cpitope o r Gag. Future hctcroclit ic studies should emphasize Gag as IIIV control is
associated with suppression or Gug. However. such studies should focus on driving
immune responses towards less imrnun odom inant regions or Gag.
While the results from our study arc promising. they do indicate a challenge for
li nding a universal therapeutic IIIV vaccine. It is likely that therapeutic IIIV vaccination
using hctcroclit ic IIIV pcptides would have to be an individualized therapy as much
variation in response exists. Although individualized therapy seems impractical. the type
or research requi red 1'0 1' peptide screening is common in III V immunology labs and is no
more laborio us than procedures carried out to optimize ART. Given that the vaccine
could induce fewer short- and long-term side effec ts, provide longer lasting effec ts
following a single administration and reduce dependence on ART. it would be cost
effe ct i ve and highly advantageous for l llVvinfcctcd individuals. There is also potential
tor over lap or pcptidcs for subgroups or individuals given that some hctcroclitic pcpt idcs
(c.g. ;\ 2-7-1. ;\ 2-Gag-3) did stimulate enhanced responses in more than one individual.
Timing or experiments was also an important factor in this study. so in order lor this
12X
approach to bc used on a practical Icvcl. there would have to minimal time between
identifying the appro priate pcptid cs I(Jr a give n ind ividual and administer ing the vacci ne,
Before an effec tive therapeutic IIIV vacc ine can be designed using this approach.
we need to determine which CT L functio ns corre late with protection and what magnitude
or response in assays co rrelates to an e ffec t ive CTL response in vivo. Interest ingly, our
IL-2-inducing hctc rocl itic pcptidcs did not stimulate more cytolytic activity than
reference peptidcs, a feature we would expec t to be required for viral con tro l. They did.
however. stim ulate IL-2 product ion. generate broadly react ive CTL. enhance proliferation
in some cases and cause a reductio n in I'D-I expression. These pcpiid cs dr ive di fferen tial
signaling or the same subset o rC DX' T cells and may reverse the ex hausted phenotype or
these ce lls. Such features illustrate the potential o r hctcrocl iiic pcptidc s to produce
dramatic eff ects and improve therapeut ic vaccina tion . Akinsik u CI (/1. 11411 showed that
IL-2 prod uction by polyfunctional l ll v- spcci fic CDX' T ce lls is assoc iated with enhanced
suppress ive capaci ty or viral repl icat ion. Perhaps had we used a similar approac h or
tested I(H'cytokinc production and cyto lytic funct ion at thc same time poin t we would
have observed similar results. Howe ver. IL-2 production by C DX' T ce lls ofte n indic.uc s
polyfunctio nality and since we only scree ned I(H' production or IL-2 and IFN-y. it is
likely that the respondi ng CT L produce other chcmoki ncs and cytoki ncs that stimulate
other cel l populations. The abi lity o r hctcroclitic pcptidcs to stimulate more broadly
reactive CT L and to red uce the ex hausted phenoty pe is idea l lor use in therape utic IIIV
vaccine s as this would activate T cel ls aga inst mul tiple IIIV variants and protect the T
ce lls from ex haustion .
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This approach would not be practica l for prevent ative vacc ine strateg ies since
hypcrstimulat ing T cells with the potent ial to be cross-reactive may result in some sell-
reactivity. especially in a case when the vaccinated individua l will never be exposed to
Ill Y. Also. if the individual has never been exposed to Il lY. we would not have an
indica tion o r which cpitopes to base our hctcrocl itic pcpiidcs on for that part icular
individual. As our study showed. no single hctcro clitic variant consistently demon strated
enhance d respon ses across all pat ients studied. However, this approac h may prove usefu l
in IIIY eradication research . Shan (;'1 ul. 12 191 showed that enhancin g CT L responses in
chronic Ill Y infection prior to reacti vat ing latent Il lY particle s. led to efficient killing o r
l ll v -infcctcd cells. Using hctcro clitic pcpt idcs to enhance specific CT L responses.
combined with eff ort s to reactivate latent proviru scs. may prove useful in eradication
".6 Study limitations and SUl-:l-:cst ions for improvement
This study had several limitations. The most promin ent or these was the limited
ava ilability or I'HMC Irom l llV vinl cctcd part icipants due to the volumes or blood
provided for resea rch purpo ses. A minimum or 6 million I'IHvlC were needed for
screening against a single peptide set to detect IFN-y and IL-2 product ion by C n g' T
cells by ELlSI'OT assay. Cryoprcscrvation or I'IHvlC often resulted in 30-70');;, cell loss.
limiting the numbcrofccl ls avai luhlc forthese expe riment s. Hccnusc o fsu ch cell loss. we
o ften could only test for IL-2 product ion in single lest as 400 .000 cells were needed per
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well for IL-2 detection. When possible. we used fresh I'BMC: however this was not
always feasible 1'0 1' several reasons. Some subjects did not donate samples regularl y thus
waiting for fresh samples would have prolonged the study. Also. since we did not know
when we would be rece iving specific samples. we would have to coat the 1:L1SI'OT
plates when the sample arri ved meaning the fresh I'IHvlC would have to be stored in the
fridge or incubator overn ight resulting in some cel l loss (~ I O'YiI) . In add ition to this. using
fresh I'BMC often resulted in higher background . One way that we could have improved
this initial screening process to use the numbe r o r cells we had more effe ctivel y would
have been to use a dual-color [ L1SI'OT assay . Boulet ('/ al. 12201 designed and validated
the high throughput dual-color ELlS I'OT assay in 2007. This assay is capable or
detect ing both IL-2 and IFN-y secreting cells simultaneously. thus reducing the ce ll input
numbe r. Ilad we used this assay. we would have been able to screen lor both cyiok incs in
duplicate and gain valuable informa tion about the percentage or C I)X' T cells that
produce d IFN-y only.IL-2 only or both .
Although the dual-color ELlSI'OT assay would allow more efficient screening. it
would not reduce the number o r cells requ ired by much. but wou ld instead allow us to
gather more inlonnari on with the ce lls we have. Therefore , we would still face the issue
or limited cell avai lability. thus precluding the ability to perform multiple assays.
Although this solution would be beneficial given our current facility and equipment. an
alternative method relying on mult ifactor flow cytomciry ( 10 ' co lors) would allow
simultaneous detection and enumeration o r peptid e-specific C I)X' T cells and provide
additional insight into their specific effec tor functions. Using this approac h. informution
131
o n cyto k inc production (IF N-y. 11.-2. TN F-u) . extra cellular mark e rs (CDli. C D451\1\ .
CC I\7 . I'D-I ). proliferati on (C FSF ). and cy to tox ic ity (pc rlo rin. gra nz yrn c B. C D I0 7a )
co uld be ga thered at o ne time point. usin g - Ix I06 I'Brvl C per peptide . T his approach
wo uld a lso el imin ate the di sad vant age s associated with 5 l C r-re lease ass ay suc h as
bio ha za rd and di spo sal problems for the isot op e . Th is co mprehe nsive a pproa c h would
a llow us to bett er determine the immu nolog ical pot en cy assoc iated with each pe pti de in
the context or ind ividu al pati ent s and would pro vid e further ins ig ht into its usc
the ra peut ic vacc ine s.
O ther limitat ion s or thi s s tudy include cave at s assoc iated with the study findin gs
themsel ves a nd cha llenges in mo ving the hctc rocliti c ap proac h to therapeuti c vacc inati on
forw a rd , In thi s s tudy . the E Ll S I'OT results art: oft en s um ma rized in term s or the pe rce nt
o fcases wh ere va riant pcptides ind uced a " s im ila r or high er " respo nse than the re fere nce
pep tide , 1100\'I:ve r. g ive n the definition o fv hctc roc litic" , thi s sho uld be sum ma rize d as
pe rcen t o r G1St:S wh ere a vari ant indu ced a better resp on se onl y . In addit io n to th is. 11.-2
respo nse s were on ly detected in a min orit y o fpa tie nts and the enh an cem ent ofrespo nses
e licited by ma ny hct cro cl it ic pcpi idcs was rel ativel y mod est co m pare d to the re ference
pcp tidc s, Th ese resp on ses a lso va ried dr asti call y OWl' time . The tem pora l incon si s ten cy
or 11.-2 respo nse s could be due to sa m pling bias due to rarity or 11.-2 pro d uc ing ce lls in
vivo . esca pe in a uto logo us vira l seq uences a nd/or III\ /\I\T-induet:d suppress io n o r vira l
load a t Io llow-up timc poi nts.
As previou sl y menti oned , no s ing le hctcroclitic c pito pc vari ant co nsi s ten tly
demonstra ted enh an ced respo nses acro ss a ll pati ent s s tud ied . Thi s re pre sents a hu ge
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problem 10 thi s approach. as unive rsa lity wou ld be di fficult 10 ac hie ve . Al so . the bu rde n
or immu ne es ca pe wi ll be high in individual s with c hronic infection , In many ca se s. the
a uto log o us viru s ma y have a lready esc aped by developing mutations that comprom ise
binding to l ll .A . Thu s. s tim ulating im m une response s to cpitopcs pre sented by particu la r
l ll .A alleles w ill requ ire knowledge or the auto logou s virus seq uence to predi ct whi c h
l ll .A mo lec ules sho uld be targeted fo r thera py . Further more. in thi s st udy . we ge ne ra ted
Il lY cpi topc var ian ts by ma king sub stitutio ns at posit ion s 3. 5. a nd 7 but not 1.4. (l . or X.
T his ap proach may not be ge nera lizab le to a ll 111./\ cla ss I a lle les nor to a ll c pito pc »
restri c ted by a g ive n a llel e , Fin all y. there arc a lso po tentia l risks invo lved us ing
hctcroc litic pep tide vacc ine stra teg ies , One such risk is ge ne rating a scq ue nce that
s tim ulates a cro ss-reactive respo nse to tissue cp itopc s cau sin g reactiv ity to sel l'.
A ltho ug h. man y sc lfpcptidcs co uld be tested in vitro 10 confirm thi s. it would be difficult
to test till ' them all.
4.7 Conclus ion
In concl usion . we identified l) IL-2- ind uc ing hetc roclit ic peptide» and se ve ra l non -
IL-2-indu c ing va rian t pcp tidc s wi th other hctc rocl it ic prop ert ies . A ltho ugh 11.-2 res po nses
we re rare . hctc rocl it ic pcpridcs cnha nc cd 11.-2 produ cti on in 50 'X,o rcase s in whi ch an 11.-
2 respon se was o bserved. T he majority o r va ria nt pcpt idcs produced a lesse r IF N-y
respon se tha n that obse rve d wi th the reference pept ide . but va rian t pcptidcs d id e nhance
IFN-y production in 25'1., or ca se s . T he high freq ue nc y or hc tcroc liti c pcptidcs ca pa ble or
IJJ
enhancing cytokinc responses by CDXt T cell s is wry promising tor future studies as a
multitude or possible hctcrocli tic peptide sequences exist for each or thc reference
pcptidcs used . Althou gh we have not elucidated the mechani sm s by which the se pept ide
act. our result s indic ate that the se pcptidcs s tim u la te the same subse ts or CDX' T cell s as
refe rence pcptidcs. but so me ho w exert se lective signaling effects. They also stim ula te
broader reactiv ity o r pe ptide -s timu la ted CDX' T ce lls, reduce the ex hau sted phe notype or
respo nding C DX' T ce lls. and. in some cases, enhance prulilcruriou or respo nding T ce lls.
Th ese feature s arc all desirab le for designin g e ff ecti ve therapeuti c Il lY vacci nes , The
structural and signaling mechanisms involved in hctcroclitic activity remain to be
elucidated . Further insight into these mechanisms would provide informution on
hctcroclitic pept ide design for Ill Y C DX' T ce ll cpi iopc s and co ntribute to a basil:
unde rstanding o f the relationship betwee n TCR/pl:ptitk interaction s and T cell function .
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Appendix A: Relati onship between 11.-2 and IFN-y IT SIHIIISCS. I'B I\1C lrom IIIV-
infected and/or l llVvuninfcctcd individuals were tested in duplicate and single test 1'01'
IFN-y and IL-2 product ion. respectively. aga inst one or more peptid e sets by 1:L1SI'OT
assay. Examples in which enhanced IL-2 producti on is correlated with high lFN-y
responses arc shown. A positive response is at least twice background and at least SO 11.-2
SFlJ/ 10t> I'BI\1C or 100 IFN-y SF LJ/ IO(' I'BI\1C The background was subtracted from the
single test value or from the average o r the dup licates. Duplicates were within 20'Y.. or
each other. The l ll.A class 1allele that presents each peptid e set is highlighted in red and
underlined .
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Appe nd ix B: Coru pur lson of ens' T cell cytotoxi t:ity induced by referen ce and
hetcruclitic pcptides II. Specific cytoto xicity o r C I)X' T cells stimulated in vitro with
reference or hctcro cl itic pcptidc s was tested, in duplicate. by 51Cr release assay against
referen ce or hctcrocl itic peptide-pulsed autologous BI.CI. target ce lls at increasing
effec to r to target rat ios. Duplicates I~ II within 20'% or each other, The 111.;\ class I al lele
that presents each peptide is highl ighted in red and underlined . Tests in which peptide -
pulsed and non-pulsed BI.CI. \\"(: 1'-: used as targets arc indicated by black triangles and
bluc squarcarcspcctivc ly,
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Appe ndix C : Compa ri sun of reference and hctcroclitic pcptide-stimulatcd-C'I'L
rea ctivit y. CT L W\: I"C stimulated in vitro with reference or hctcrocl itic pcptidcs and
tested, in dupl icate, by 51Cr release assay agai nst !l LC L pulsed with each peptide within a
set, For #00 1. the refere nce peptide did not induce CT L therefore crossrcactiv ity could
not be assessed . Duplicates tell within 20'% o f each other. The l ll.A class I alle le that
presents each peptide is highl ighted in red and underlined, The effector to targd rat io
used is indi cated be low each headin g,
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